<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Fluids Barriers CNS</journal-id><journal-id journal-id-type="iso-abbrev">Fluids Barriers CNS</journal-id><journal-id journal-id-type="pmc-domain-id">1454</journal-id><journal-id journal-id-type="pmc-domain">fbcns</journal-id><journal-title-group><journal-title>Fluids and Barriers of the CNS</journal-title></journal-title-group><issn pub-type="epub">2045-8118</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC3602026</article-id><article-id pub-id-type="pmcid-ver">PMC3602026.1</article-id><article-id pub-id-type="pmcaid">3602026</article-id><article-id pub-id-type="pmcaiid">3602026</article-id><article-id pub-id-type="pmid">23432852</article-id><article-id pub-id-type="doi">10.1186/2045-8118-10-12</article-id><article-id pub-id-type="publisher-id">2045-8118-10-12</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name name-style="western"><surname>de Lange</surname><given-names initials="ECM">Elizabeth CM</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>l.lange@lacdr.leidenuniv.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Pharmacology, Leiden-Academic Center for Drug Research, Leiden University, Leiden, the Netherlands</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>22</day><month>2</month><year>2013</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">218999</issue-id><fpage>12</fpage><lpage>12</lpage><history><date date-type="received"><day>17</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>1</day><month>2</month><year>2013</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>02</month><year>2013</year></date></event><event event-type="pmc-live"><date><day>20</day><month>03</month><year>2013</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-05 07:25:10.930"><day>05</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169;2013 De Lange; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>De Lange; licensee BioMed Central Ltd.</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="2045-8118-10-12.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.fluidsbarrierscns.com/content/10/1/12"/><abstract><p>Despite enormous advances in CNS research, CNS disorders remain the world&#8217;s leading cause of disability. This accounts for more hospitalizations and prolonged care than almost all other diseases combined, and indicates a high unmet need for good CNS drugs and drug therapies.</p><p>Following dosing, not only the chemical properties of the drug and blood&#8211;brain barrier (BBB) transport, but also many other processes will ultimately determine brain target site kinetics and consequently the CNS effects. The rate and extent of all these processes are regulated dynamically, and thus condition dependent. Therefore, heterogenious conditions such as species, gender, genetic background, tissue, age, diet, disease, drug treatment etc., result in considerable inter-individual and intra-individual variation, often encountered in CNS drug therapy.</p><p>For effective therapy, drugs should access the CNS &#8220;<italic toggle="yes">at the right place</italic>, <italic toggle="yes">at the right time</italic>, <italic toggle="yes">and at the right concentration&#8221;</italic>. To improve CNS therapies and drug development, details of inter-species and inter-condition variations are needed to enable target site pharmacokinetics and associated CNS effects to be translated between species and between disease states. Specifically, such studies need to include information about unbound drug concentrations which drive the effects. To date the only technique that can obtain unbound drug concentrations in brain is microdialysis. This (minimally) invasive technique cannot be readily applied to humans, and we need to rely on translational approaches to predict human brain distribution, target site kinetics, and therapeutic effects of CNS drugs.</p><p>In this review the term &#8220;Mastermind approach&#8221; is introduced, for strategic and systematic CNS drug research using advanced preclinical experimental designs and mathematical modeling. In this way, knowledge can be obtained about the contributions and variability of individual processes on the causal path between drug dosing and CNS effect in animals that can be translated to the human situation. On the basis of a few advanced preclinical microdialysis based investigations it will be shown that the &#8220;Mastermind approach&#8221; has a high potential for the prediction of human CNS drug effects.</p></abstract><kwd-group><kwd>CNS drug therapy</kwd><kwd>Brain distribution</kwd><kwd>Translational research</kwd><kwd>Microdialysis</kwd><kwd>Target site concentrations</kwd><kwd>Prediction</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><title>Introduction</title><p>Central nervous system (CNS) disorders are currently estimated to affect hundreds of millions of people worldwide [<xref ref-type="bibr" rid="B1">1</xref>]. While established treatments are currently available for most CNS disorders, significant unmet medical needs still remain. This is partly because currently available drugs merely treat symptoms rather than cure the disease, and may also elicit unwanted side effects. The attrition rate in CNS drug development is high and there is a need for revised approaches to improve CNS drug development and therapies.</p><p>It is often thought that the blood&#8211;brain barrier (BBB) hampers the adequate distribution of CNS drugs into the brain resulting in a lack of effects [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. However, this cannot be the sole reason because other factors besides BBB transport determine the concentration-time profile (pharmacokinetics, PK) of the unbound drug at the brain target site [<xref ref-type="bibr" rid="B5">5</xref>]. Other important factors are plasma pharmacokinetics, plasma protein binding, cerebral blood flow, effective brain capillary surface area, blood-cerebrospinal fluid-barrier (BCSFB) transport, intracerebral distribution, CSF turnover, extracellular fluid (ECF) bulk flow, extra-intracellular exchange, brain tissue binding, and drug metabolism [<xref ref-type="bibr" rid="B5">5</xref>]. These factors are controlled by many processes, each of which has a specific influence [<xref ref-type="bibr" rid="B6">6</xref>], thereby playing a more or less important role in delivering the CNS drug to the <italic toggle="yes">right place</italic>, at the <italic toggle="yes">right time</italic>, and at the <italic toggle="yes">right concentration</italic>.</p><p>Apart from the multiple processes on the causal path between drug dosing and response, inter- and intra-individual variability in the contribution of each process to the ultimate CNS effect (pharmacodynamics, PD) need to be identified. This variability is caused by dissimilarities in genetic background, species, tissue, age, diet, disease, and drug treatment (heterogeneity) and associated differences in rate and extent of the individual processes on the causal chain between drug dosing and CNS effects. This explains why the same dose in different conditions may result in different CNS effects.</p><p>Investigations of the PK-PD relationship of a CNS drug should therefore be designed such that the contribution of a particular process is identified (for example by systematically influencing the process), and that information is obtained on time-dependency and on the unbound plasma and target tissue drug concentrations that drive the effect. To that end, advanced mathematical modeling is a prerequisite to learn about the contributions of individual processes in drug PK-PD relationships. This approach is here introduced as the &#8220;Mastermind approach&#8221;.</p><p>Noninvasive imaging techniques like positron emission tomography (PET), nuclear magnetic resonance (NMR) or (functional) magnetic resonance imaging ((f)MRI) are powerful methods to obtain information on transporter functionality [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>], and target occupation [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. These techniques may improve understanding of the influence of drug action on brain functionality in health and disease [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. However, additional information is also needed about the unbound drug concentrations in the brain. In humans, at best, cerebrospinal fluid (CSF) concentrations can be obtained as a surrogate for brain target site concentrations [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B16">16</xref>], but the value of this surrogate is questionable [<xref ref-type="bibr" rid="B17">17</xref>]. To date, brain microdialysis is the only technique to obtain quantitative and time-resolution data on unbound extracellular drug concentrations in the brain (brain ECF) [<xref ref-type="bibr" rid="B18">18</xref>]. Although minimally invasive, microdialysis is a technique that can be applied in human brain only under highly restricted conditions [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. Thus, we should pursue preclinical studies to learn about CNS target site distribution of drugs. This review will discuss the physiological factors involved in brain distribution and CNS effects, and the variability in these factors caused by heterogeneity. Furthermore it will provide examples of Mastermind approaches using microdialysis for quantitative assessment of 1) intracerebral distribution for drugs with different physico-chemical properties, 2) preclinical CNS target site concentrations following different routes of administration, 3) prediction of human CNS target site concentrations and CNS effects.</p><sec><title>Physiological factors in intracerebral distribution, drug target site kinetics, and CNS drug effects</title><p>The anatomy of the CNS is complex and can grossly be divided into four main compartments [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B25">25</xref>]: the brain extracellular fluid (brain ECF) compartment, brain intracellular compartment, and the ventricular and lumbar CSF compartments. Transport of drugs into, within and out of the brain is governed by the blood&#8211;brain barriers, the anatomy of the brain parenchyma and fluid spaces, physiological processes, and drug-specific properties [<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B32">32</xref>]. In combination, they determine the concentrations of a drug within a specific region of the CNS, including the unbound concentration at the target site that drives the effect (Figure&#160;<xref ref-type="fig" rid="F1">1</xref>). The players in drug exchange are briefly presented here.</p><fig id="F1" position="float" orientation="portrait"><label>Figure 1</label><caption><p><bold>Schematic presentation of the major compartments of the mammalian brain and routes for drug exchange; extracellular fluid (ECF), brain cells, lateral ventricular CSF, cisterna magna CSF and lumbar CSF, passive transport (black arrows) and active transport (white arrows), as well as metabolism and CSF turnover.</bold> Drug targets may be present at different sites within the brain.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2045-8118-10-12-1.jpg"/></fig><sec><title>Unbound concentrations in plasma</title><p>Only the unbound (free) drug is able to pass through membranes, and it is the unbound concentration in plasma that drives transport into the brain. Then, the unbound concentration at the CNS target site drives the interaction with the target and therewith the CNS effect (unbound drug hypothesis) [<xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B35">35</xref>]. In specific cases when the brain acts as a sink, total plasma concentrations may be relevant. Also, if a BBB transporter affinity and capacity is significantly larger than that for plasma proteins, &#8220;stripping&#8221; occurs and clearance can be based on the total plasma concentration. </p><p>Unbound drug concentration is crucial for our understanding of drug transport and target interaction [<xref ref-type="bibr" rid="B36">36</xref>]. Often, the &#8220;unbound fraction&#8221; and &#8220;unbound concentration&#8221; are used interchangeably which leads to confusion: the &#8220;unbound fraction&#8221; is calculated from the ratio of unbound to total concentration [<xref ref-type="bibr" rid="B37">37</xref>-<xref ref-type="bibr" rid="B39">39</xref>]. So, it is the unbound concentration profile (kinetics) of the drug that should ultimately be taken into account to understand drug effects.</p></sec><sec><title>Transport across the brain barriers</title><p>The blood&#8211;brain barrier (BBB) and the blood-CSF-barrier (BCSFB) govern drug transfer into and out of the brain [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B44">44</xref>]. These barriers are comparable in many ways, but also have their specific characteristics [<xref ref-type="bibr" rid="B45">45</xref>-<xref ref-type="bibr" rid="B47">47</xref>]. The BBB consists of cerebrovascular endothelial cells while the BCSFB consists of choroid plexus epithelial cells. Together with the BBB and BCSFB transport characteristics and surface areas, the drug characteristics (lipophilicity, size, shape, charge, affinity for a transporter etc., Figure&#160;<xref ref-type="fig" rid="F2">2</xref>) determine the actual transport rate and extent. Recent investigations have indicated that the basal and apical membranes of the BCSFB have extensive infoldings and microvilli, respectively, suggesting that the BCSFB surface area, maybe the same order of magnitude as for the BBB [<xref ref-type="bibr" rid="B48">48</xref>].</p><fig id="F2" position="float" orientation="portrait"><label>Figure 2</label><caption><p><bold>Factors affecting the pharmacokinetics and pharmacodynamics of a drug.</bold> The effects of a drug are determined on one hand by its physico-chemical/molecular characteristics and on the other hand by the properties of the biological systems involved.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2045-8118-10-12-2.jpg"/></fig><p>There are a number of basic modes for compounds to move across brain barrier membranes [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>]:</p><p>&#8226;Simple diffusion is a passive process driven by the concentration gradient, from high to low concentrations. The rate of diffusion is proportional to the concentration difference between compartments of the diffusing molecule. At equilibrium the concentration of the diffusing molecules are equal at both sides of the membrane. This mode of transport is size-dependent and permeability limited [<xref ref-type="bibr" rid="B51">51</xref>]. For hydrophilic drugs, not able to diffuse through lipophilic membranes, movement through the space between neighbouring barrier cells (paracellular transport) is restricted by the presence of tight junctions. [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B50">50</xref>].</p><p>&#8226;Facilitated diffusion is also a passive process from high to low concentrations but requires a helper molecule [<xref ref-type="bibr" rid="B52">52</xref>-<xref ref-type="bibr" rid="B54">54</xref>]. The rate of diffusion is limited by the availability of the helper molecules and at equilibrium the concentration of the diffusing molecules are equal on both sides of the membrane. Once all the helper molecules are saturated, increasing the concentration of diffusing molecules will only increase a waiting line for the helper molecules and will not increase rate of transport further. Facilitated transport is subject to competitive inhibition by substrate analogs and contributes to transport at the BBB of substances such as monocarboxyates, hexoses, amines, amino acids, nucleosides, glutathione, and small peptides.</p><p>&#8226;Fluid phase (vesicular) transport [<xref ref-type="bibr" rid="B55">55</xref>,<xref ref-type="bibr" rid="B56">56</xref>] includes bulk flow endocytosis (pinocytosis), adsorptive-mediated endocytosis, and receptor-mediated endocytosis [<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B58">58</xref>]. Pinocytosis is the non-specific uptake of extracellular fluids. It is temperature and energy dependent, non-competitive, and non-saturable. Under physiological conditions, it occurs to a very limited degree in cerebral endothelial cells. Adsorptive-mediated endocytosis involves endocytosis in vesicles of charged substances by a non-specific mechanism [<xref ref-type="bibr" rid="B59">59</xref>,<xref ref-type="bibr" rid="B60">60</xref>]. Receptor-mediated transcytosis uses vesicles formed upon binding of large macromolecules to specific receptors [<xref ref-type="bibr" rid="B61">61</xref>]. At the BBB, transport of vesicles occurs only in direction from blood to brain. Vesicles may be subject to degradation within the cell, otherwise they are able to deliver their content to the abluminal side and into the brain.</p><p>&#8226;Active transport occurs by the action of membrane transport proteins for which transported molecules have a specific binding site. It requires energy and can transport substrates against a concentration gradient. Active transport is temperature sensitive and can become saturated. It can also be influenced by competitive and noncompetitive inhibitors and by interference with transporter protein phosphorylation by protein kinases. Transport proteins may have an important impact on drug development [<xref ref-type="bibr" rid="B62">62</xref>]. Transport systems [<xref ref-type="bibr" rid="B63">63</xref>] are directional (influx and/or efflux), and serve to maintain brain homeostasis for endogenous compounds. However, in numerous cases drugs may also be ligands for these transporters [<xref ref-type="bibr" rid="B64">64</xref>-<xref ref-type="bibr" rid="B70">70</xref>]. As a consequence, efflux transporters at the BBB have gained enormous attention over the last decade. Their presence accounts for the fact that many drugs, despite their lipophilic character favorable for passive transport, have a relatively poor brain distribution because they are substrates. The best known efflux transporters are P-glycoprotein (P-gp, or officially ABCB1 [<xref ref-type="bibr" rid="B71">71</xref>,<xref ref-type="bibr" rid="B72">72</xref>]), the multidrug resistance-related proteins (MRP&#8217;s, or officially ABCC&#8217;s [<xref ref-type="bibr" rid="B73">73</xref>]) and the breast cancer resistance protein (BCRP, or officially ABCG2 [<xref ref-type="bibr" rid="B74">74</xref>]), which all belong to the ABC transporter family [<xref ref-type="bibr" rid="B75">75</xref>].</p></sec><sec><title>Cerebral blood flow and effective capillary surface area</title><p>For drugs with high BBB permeation such that entry to the brain via the BBB capillaries is rapid, cerebral blood flow becomes rate-limiting. Cerebral blood flow can be influenced by changes in linear flow rate or by changes in the number of perfused capillaries. When the linear velocity of blood flow is increased, influx of highly permeable drugs across the BBB will increase (and <italic toggle="yes">vice versa</italic>), while BBB transport of slightly-to-virtually impermeable drugs will essentially be unchanged. Variations in the total number of the perfused capillaries in the brain (&#8220;effective perfusion&#8221;) will in theory affect BBB transport of all drugs [<xref ref-type="bibr" rid="B76">76</xref>,<xref ref-type="bibr" rid="B77">77</xref>].</p></sec><sec><title>CSF turnover and ECF bulk flow</title><p>CSF is produced by the choroid plexus [<xref ref-type="bibr" rid="B78">78</xref>] in the ventricles and leaves the CNS by re-absorption back into blood via the arachnoid villi in the subarachnoid space. CSF turnover [<xref ref-type="bibr" rid="B79">79</xref>] may reduce CSF drug concentrations [<xref ref-type="bibr" rid="B80">80</xref>]. The slower the permeation of a drug into the CSF, the more influence CSF turnover will have on the CSF concentration relative to its plasma concentration. Also, because of the relatively slow rate of CSF turnover in relation to trans-capillary transport, brain ECF concentrations will equilibrate more rapidly with plasma concentrations than with CSF. Furthermore, there is bulk flow of extracellular fluid into the CSF [<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B81">81</xref>] that could counteract any molecular diffusion that might occur from the CSF into brain tissue through the ependymal linings of the ventricles [<xref ref-type="bibr" rid="B82">82</xref>].</p></sec><sec><title>Extra-intracellular exchange and brain tissue binding</title><p>Drugs may have their preference for extracellular or intracellular space, and may be subjected to nonspecific binding to brain tissue components [<xref ref-type="bibr" rid="B83">83</xref>]. Drug distribution between brain cells and extracellular space does not only occur by simple diffusion: active transport may also occur at brain cell membranes [<xref ref-type="bibr" rid="B68">68</xref>,<xref ref-type="bibr" rid="B84">84</xref>]. Distribution between extra- and intracellular compartments is very important for exposure of <italic toggle="yes">unbound</italic> drug concentrations at the target site (Figure&#160;<xref ref-type="fig" rid="F1">1</xref>) [<xref ref-type="bibr" rid="B85">85</xref>]. It can be seen that it is important to know the location of the target in order to optimize concentration profiles and drug effects.</p></sec><sec><title>Drug metabolism</title><p>Brain distribution may also be influenced by metabolism of the drug. This may occur at the level of the BBB and BCSFB, serving as &#8220;enzymatic barriers&#8221; to drug influx into brain, and also in the ependymal cells lining the CSF ventricles potentially influencing intracerebral distribution [<xref ref-type="bibr" rid="B86">86</xref>-<xref ref-type="bibr" rid="B89">89</xref>]. In brain blood vessels and closely-surrounding cell types, enzymes like cytochrome P450 haemoproteins, several cytochrome P450-dependent monooxygenases, NADPH-cytochrome P450 reductase, epoxide hydrolase, and also conjugating enzymes such as UDP-glucuronosyltransferase and &#945;-class glutathione S-transferase have been detected. Several enzymes involved in hepatic drug metabolism have been found in brain microvessels and the choroid plexus. In the choroid plexus, very high activities (similar to those in the liver) have been found for UDP-glucuronosyltransferase and epoxide hydrolase, and several cytochrome P450 isoenzymes are also relatively high. Relatively high values of &#945; and &#956; classes of glutathione S-transferase and glutathione peroxidase have been found in both the BBB and BCSFB.</p></sec><sec><title>Target interaction</title><p>The association and dissociation kinetics of a drug at the target (target interaction) is another factor to be taken into account for the relationship between drug concentration and CNS effect. Such interaction is not always instantaneous. For example, the opioid buprenorphine has slow kinetics for both receptor association and receptor dissociation. Such information was crucial to predict that reversal of respiratory depression caused by opioids could be achieved by the antagonist naloxone if naloxone is administered as a continuous infusion [<xref ref-type="bibr" rid="B90">90</xref>].</p></sec><sec><title>Signal transduction and homeostatic processes</title><p>It is frequently assumed that pharmacological responses depend solely on the extent of drug binding to its receptor (occupational theory). However, when observing tolerance, sensitization, dependence, and abstinence, it is clear that pharmacological responses <italic toggle="yes">in vivo</italic> can be subjected to modulation by homeostatic mechanisms. Thus, an integrative physiological approach is needed to understand concentration-effect relationships [<xref ref-type="bibr" rid="B91">91</xref>].</p></sec></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Transport of drugs into the brain, within the brain and to the brain target site, and the resulting CNS effect are determined by many factors. Having information on just one of these factors in isolation is insufficient to predict target site distribution, let alone CNS drug effects.</p><sec><title>Heterogeneity as a source of variability in brain distribution and CNS effects</title><sec><title>Heterogeneity</title><p>Mammals mostly share the same biological processes, which form the basis for interspecies extrapolation in drug development. However, problems arise with variable rates and extents in the processes on the causal path between drug administration and CNS effects. Below, examples of the impact of heterogeneity are addressed.</p></sec><sec><title>Genetic background</title><p>Genetic polymorphisms exist in the human MDR1 (P-gp) gene and may have clinical consequences [<xref ref-type="bibr" rid="B92">92</xref>,<xref ref-type="bibr" rid="B93">93</xref>]. In the clinical response to antidepressants, genetic factors in particular, are considered to contribute to variability. Variants affect the function of genes involved in both drug concentrations and CNS effects. Genetic variants affecting the metabolism of antidepressants may change pharmacokinetic factors, polymorphisms can affect receptor function, while signal transduction molecules may alter the pharmacodynamics [<xref ref-type="bibr" rid="B94">94</xref>]. A specific example is the effect of nicotine on heart rate. As much as 30% of the variance in the acceleration of heart rate was due to additive genetic sources, as determined in a study using a monozygotic and dizygotic twin population [<xref ref-type="bibr" rid="B95">95</xref>].</p></sec><sec><title>Species differences</title><p>Species differences occur in P-gp functionalities, also at the level of the BBB [<xref ref-type="bibr" rid="B7">7</xref>]. It was found that rhesus monkey P-gp is much closer to human P-gp than to beagle dog P-gp [<xref ref-type="bibr" rid="B96">96</xref>]. Also, the effects of inhibitors on P-gp functionality appear to be species dependent [<xref ref-type="bibr" rid="B97">97</xref>]. <italic toggle="yes">In vivo</italic> studies using PET imaging have also reported species differences in P-gp functionality [<xref ref-type="bibr" rid="B7">7</xref>].</p></sec><sec><title>Effect of gender</title><p>Sex hormones all influence the function and pathophysiology of the cerebral circulation [<xref ref-type="bibr" rid="B98">98</xref>]. Estrogen has numerous effects on dopamine neurotransmission, and because the incidence of Parkinson&#8217;s disease is lower in women than in men its possible use to either slow the progression or reduce the risk of Parkinson&#8217;s disease has been considered [<xref ref-type="bibr" rid="B99">99</xref>]. In schizophrenic patients, gender differences have been found in the pituitary secretion of prolactin, growth hormone, and thyroid-stimulating hormone in response to neuroleptic drug treatment [<xref ref-type="bibr" rid="B100">100</xref>]. Also, differences exist between female and male sensitivities to anesthesia and opioids [<xref ref-type="bibr" rid="B101">101</xref>].</p></sec><sec><title>Effect of age</title><p>Many studies indicate the importance of age in PK and/or PD. Age seems to affect P-gp functionality at the BBB [<xref ref-type="bibr" rid="B102">102</xref>], which may have consequences for brain efflux of P-gp substrates. Some of the properties of glucocorticoid receptors change with age [<xref ref-type="bibr" rid="B103">103</xref>]. Binding to the NMDA binding site by L-glutamate and/or antagonists, decreases with increasing age in the cerebral cortex and hippocampus, regions that are important for memory processing [<xref ref-type="bibr" rid="B104">104</xref>]. Important changes starting at mid-life in neuroanatomy, neurochemistry and endogenous pain inhibition may be associated with alterations in pain sensitivity [<xref ref-type="bibr" rid="B105">105</xref>]. Another example is impaired neurotransmission that may be responsible for at least some of the behavioral abnormalities associated with aging [<xref ref-type="bibr" rid="B106">106</xref>].</p></sec><sec><title>Effect of diet</title><p>Mulder <italic toggle="yes">et al.</italic>[<xref ref-type="bibr" rid="B107">107</xref>] have shown that the <italic toggle="yes">combination</italic> of a high-fat diet and APOe4 knockout conditions in mice resulted in a loss of BBB functionality. This leads to an increase BBB permeability, resulting in increased IgG staining and increased fluorescein distribution in the brain. Also, red wine polyphenolic contents influence Alzheimer&#8217;s disease-type neuropathology and cognitive deterioration, in a component-specific manner [<xref ref-type="bibr" rid="B108">108</xref>].</p></sec><sec><title>Disease states</title><p>In the rat pilocarpine model of epilepsy, increased brain concentration of the active metabolite of oxcarbazepine was observed following seizures together with inhibition of BBB efflux transport, but without changes in plasma concentrations. This indicated that a distributional process is changed at the level of the BBB in epileptic conditions [<xref ref-type="bibr" rid="B109">109</xref>]. Changes in BBB permeability during electrically-induced seizures in human have also been observed [<xref ref-type="bibr" rid="B110">110</xref>]. A change in P-gp expression at the BBB has been reported in humans with the human immunodeficiency virus [<xref ref-type="bibr" rid="B111">111</xref>]. Tunblad <italic toggle="yes">et al.</italic> reported the impact of meningitis on morphine distribution in piglet brain, indicating decreased BBB functionality [<xref ref-type="bibr" rid="B112">112</xref>]. Also, after subcutaneous infusion of rotenone in rats, changes in BBB permeability for fluorescein occur as a result of induced peripheral inflammation but without any biomarkers for Parkinson&#8217;s disease [<xref ref-type="bibr" rid="B113">113</xref>]. In contrast, the unilateral brain infusion of rotenone did induce biomarkers for Parkinson&#8217;s disease, but no changes in BBB permeability for fluorescein and the large neutral amino acid transporter-mediated BBB transport of L-DOPA [<xref ref-type="bibr" rid="B114">114</xref>].</p></sec><sec><title>Drug treatment</title><p>Cleton <italic toggle="yes">et al.</italic>[<xref ref-type="bibr" rid="B115">115</xref>] found changes in the relationship between long-term treatment effects of midazolam and its concentration-EEG effect which, however, were unrelated to changes in benzodiazepine receptor function. Other examples are the alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine which appeared to correlate with dyskinesia induction in MPTP-treated marmosets [<xref ref-type="bibr" rid="B116">116</xref>], the tolerance to diazepam after chronic use [<xref ref-type="bibr" rid="B117">117</xref>], and the onset of hyperalgesia by opioid treatment [<xref ref-type="bibr" rid="B118">118</xref>].</p></sec><sec><title>Heterogeneity results in variability</title><p>Heterogeneity in genetic background, species, gender, tissue, age, diet, (pathologic) conditions, drug treatment, are underlying the variability in rate and extent of individual processes. This explains why the same dose in different subjects may result in different effects. It is therefore surprising that, in most cases, the dose-effect or at best the plasma-effect relationships continue to be used for extrapolation.</p></sec></sec><sec><title>Need for quantitative and integral [&#8220;mastermind&#8221;] approaches</title><sec><title>Heterogeneity</title><p>As has been shown, there are many factors that play a role in the PK-PD relationships of CNS drugs. The rates and extents of the multiple processes on the causal path between drug dosing and CNS can be highly diverse. Therefore, data obtained in a particular condition are not necessarily predictive of that in another condition. But, as living mammals mostly share the same biological processes, knowledge of rate and extent of individual processes provide the foundation for interspecies extrapolation in drug development [<xref ref-type="bibr" rid="B119">119</xref>-<xref ref-type="bibr" rid="B122">122</xref>].</p></sec><sec><title>Translation from animal to human, the mastermind approach</title><p>Because in the body (biological system) multiple processes as are working concurrently, there is a need for integrated <italic toggle="yes">in vivo</italic> experiments. This means that the experiments should obtain data on multiple processes as much as possible from the same subject, in a time-dependent and quantitative manner. This also means that we have to address heterogeneity of the rates and extents of physiological processes on the causal path between drug administration and CNS effects and have to use study designs in which individual processes can be challenged. This can be done, for example, by changing plasma protein binding [<xref ref-type="bibr" rid="B123">123</xref>,<xref ref-type="bibr" rid="B124">124</xref>], inhibition of a particular efflux transporter [<xref ref-type="bibr" rid="B125">125</xref>], blocking particular receptors [<xref ref-type="bibr" rid="B126">126</xref>,<xref ref-type="bibr" rid="B127">127</xref>], or by induction of a pathological state [<xref ref-type="bibr" rid="B113">113</xref>,<xref ref-type="bibr" rid="B128">128</xref>] and enabling us to learn about the contribution of individual processes in CNS target site kinetics [<xref ref-type="bibr" rid="B17">17</xref>] and dynamics [<xref ref-type="bibr" rid="B129">129</xref>,<xref ref-type="bibr" rid="B130">130</xref>].</p><p>Here is the place to introduce the term &#8220;Mastermind approach&#8221; as an allegory. In the game &#8220;Mastermind&#8221; there are pins with different colors, and different positions in which part of the colors can be positioned. By systematically and strategically varying the position and colors of the pins the &#8220;code&#8221; can be ultimately deciphered. With each colors representing a particular mechanism, the code represents a particular PK-PD relationship. Of course, the dose-effect relationship of CNS drugs includes many more variables than the number of differently colored pins in the Mastermind game, and this is the reason that we just cannot interpret the data solely by &#8220;eye-ball analysis&#8221; and need to use advanced mathematical modeling [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B129">129</xref>-<xref ref-type="bibr" rid="B132">132</xref>]. In doing so, we need to make a strict distinction between the properties of drugs and the properties of biological systems to predict drug behavior under different conditions.</p><p>The physiologically-based pharmacokinetic (PBPK) modeling approach has provided the basis for interspecies extrapolation, has focused on quantitative modeling of mass transport into and out of physiological compartments, and has made highly significant contributions to knowledge of systems and the fates of drugs [<xref ref-type="bibr" rid="B133">133</xref>]. It has not, however, specifically taken into account the distinction between the bound and unbound drug. With the introduction of the microdialysis technique, information on unbound drug concentrations has become available and is providing the next step in physiologically-based modeling. Below, studies are presented that explicitly show the value of knowledge of unbound drug concentrations, as obtained by intracerebral microdialysis.</p></sec></sec><sec><title>Applications of the mastermind approach</title><sec><title>Impact of drug properties on intracerebral distribution</title><p>For prediction of CNS drug action, it is important to have information of unbound drug concentrations at its CNS target site in humans. However, this is limited by the inaccessibility of the human brain for sampling. Moreover, it is often difficult to quantify human CNS drug effects indicating that effects in humans should be predicted by other approaches. As a surrogate for the concentrations of unbound drug at target sites, CSF concentrations are often used and considered appropriate [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B83">83</xref>], however, a generally applicable relationship between CSF and brain ECF concentrations is questionable [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B134">134</xref>]. Therefore, it is of interest to investigate the relationship between the two, for different drugs and under different conditions, to discover what general principles exist. In our laboratory such studies were performed for acetaminophen [<xref ref-type="bibr" rid="B135">135</xref>] and quinidine whose physico-chemical properties are shown in Table&#160;<xref ref-type="table" rid="T1">1</xref>. Experiments in rats were performed using intravenous drug administration and concurrent sampling of blood and collection of microdialysis fluid from probes located in brain striatum ECF, lateral ventricle CSF, and cisterna magna CSF (Figure&#160;<xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F3" position="float" orientation="portrait"><label>Figure 3</label><caption><p><bold>Longitudinal section of the rat brain (From: Paxinos and Watson </bold>[<xref ref-type="bibr" rid="B136">136</xref>]<bold>) with the positions of the microdialysis probes indicated. From left to right: probe position in striatum, lateral ventricle CSF and cisterna magna CSF, respectively.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2045-8118-10-12-3.jpg"/></fig><p>&#8226;Acetaminophen:</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Physico-chemical properties of acetaminophen and quinidine</p></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="top"><tr><th align="left" colspan="1" rowspan="1"><bold>Compound</bold></th><th align="left" colspan="1" rowspan="1"><bold>MW</bold></th><th align="left" colspan="1" rowspan="1"><bold>PSA</bold></th><th align="left" colspan="1" rowspan="1"><bold>logP</bold></th><th align="left" colspan="1" rowspan="1"><bold>logD[7.4]</bold></th><th align="left" colspan="1" rowspan="1"><bold>pKa1 [Acid]</bold></th><th align="left" colspan="1" rowspan="1"><bold>pKa2 [Acid]</bold></th><th align="left" colspan="1" rowspan="1"><bold>pKa1 [Base]</bold></th><th align="left" colspan="1" rowspan="1"><bold>pKa1 [Base]</bold></th><th align="left" colspan="1" rowspan="1"><bold>Ionized at physiological pH</bold></th><th align="left" colspan="1" rowspan="1"><bold>Substrate for</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom" colspan="1" rowspan="1">Acetaminophen<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">151<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">49,3<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">0,25<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">0,23<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">&#160;<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">&#160;<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">&#160;<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">10,2<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">0% [neutral]<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">-<hr/></td></tr><tr><td align="left" colspan="1" rowspan="1">Quinidine</td><td align="left" colspan="1" rowspan="1">324</td><td align="left" colspan="1" rowspan="1">45,6</td><td align="left" colspan="1" rowspan="1">2,29</td><td align="left" colspan="1" rowspan="1">1,4</td><td align="left" colspan="1" rowspan="1">4,2</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">99.8% [positive]</td><td align="left" colspan="1" rowspan="1">Pgp</td></tr></tbody></table><table-wrap-foot><p>MW&#8201;=&#8201;molecular weight, PSA&#8201;=&#8201;polar surface area, Log P&#8201;=&#8201;measure of lipophilicity determined as log of partition of un-ionised compound over octanol/water, Log D[7.4]&#8201;=&#8201;measure of lipophilicity at physiological pH, determined as log of distribution of the compound over octanol/ buffer pH&#8201;=&#8201;7.4.</p></table-wrap-foot></table-wrap><p>For acetaminophen the resulting unbound concentration-time profiles in plasma, brain ECF and CSF in lateral ventricle and cisterna magna are presented in Figure&#160;<xref ref-type="fig" rid="F4">4</xref>[<xref ref-type="bibr" rid="B135">135</xref>], and indicate rapid equilibration with plasma concentration. However, brain ECF concentrations are on average 4-fold higher than CSF concentrations, with average brain-to-plasma [AUC<sub>0-240</sub>] ratios of 1.2, 0.30 and 0.35 for brain ECF, lateral ventricle CSF and cisterna magna CSF, respectively. This shows that even for a compound with only passive transport into, within and out of the brain, differences exist between brain ECF and the CSF pharmacokinetics. A physiologically-based pharmacokinetic model was developed [<xref ref-type="bibr" rid="B135">135</xref>]. This model included the central (plasma) and peripheral tissue compartments and, for the brain, the brain intracellular space (brain ICS), brain extracellular fluid (brain ECF), lateral ventricle CSF, cisterna magna CSF and also subarachnoid space CSF (CSF SAS) was included. The latter is important with regard to prediction of lumbar CSF concentrations in human, as lumbar CSF is part of the SAS CSF that can be distinctively different from ventricular or cisterna magna CSF (as predicted for acetaminophen by this model [<xref ref-type="bibr" rid="B135">135</xref>]). This physiologically-based pharmacokinetic model was turned into a human model, by replacing the rat physiological parameters by those in human (Table&#160;<xref ref-type="table" rid="T2">2</xref>). The resulting model was used to predict plasma and CSF concentrations in human, and the plasma and SAS CSF concentrations of acetaminophen predicted by the model could be compared to actual data obtained in human by Bannwarth <italic toggle="yes">et al.</italic>[<xref ref-type="bibr" rid="B137">137</xref>]. The model successfully predicted the available human plasma and SAS CSF data (Figure&#160;<xref ref-type="fig" rid="F5">5</xref>). This gives us confidence in the method for prediction of human brain ECF concentrations, as best possible reflection of target site concentrations.</p><fig id="F4" position="float" orientation="portrait"><label>Figure 4</label><caption><p><bold>Brain distribution of acetaminophen in the rat. a</bold>) Data obtained for acetaminophen in the rat following an intravenous dose of 15&#160;mg/kg, administered by constant-rate infusion for 10&#160;minutes. The data are presented as the average (geometric mean&#8201;&#177;&#8201;SEM) of the observed unbound acetaminophen concentration-time profiles in plasma (black, n&#8201;=&#8201;10), striatum ECF (ST, blue, n&#8201;=&#8201;10), CSF in lateral ventricle (LV, green, n&#8201;=&#8201;14), and CSF in cisterna magna (CM, red, n&#8201;=&#8201;8). The data show that brain ECF (striatum) concentrations are comparable to those in plasma and significantly higher than those in both the lateral ventricle and the cisterna magna CSF compartments. <bold>b</bold>) The physiologically-based pharmacokinetic model for the rat developed on the basis of the data obtained for acetaminophen as shown in a). This model describes the obtained data adequately, and predicts the CSF acetaminophen concentrations in the third and fourth ventricle (lumped as TFV) as well as in the subarachnoid space (SAS), the latter being most representative of the lumbar CSF concentrations [<xref ref-type="bibr" rid="B135">135</xref>]. Denotations: In the model clearance (CL, volume/time), and ECF bulk or CSF flow (Q, volume/time) are indicated. Numbering indicates exchange between different compartments: 12 from plasma to peripheral compartment; 21 from peripheral to plasma compartment; 13 from plasma to brain ECF compartment; 31 from brain ECF to plasma compartment; 14 from plasma to CSF<sub>LV</sub> compartment; 41 from CSF<sub>LV</sub> to plasma compartment; 15 from plasma to CSF<sub>TFV</sub> compartment; 51 from CSF<sub>TFV</sub> to plasma compartment; 16 from plasma to CSF<sub>CM</sub> compartment; and 61 from CSF<sub>CM</sub> to plasma compartment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2045-8118-10-12-4.jpg"/></fig><fig id="F5" position="float" orientation="portrait"><label>Figure 5</label><caption><p><bold>Observed and predicted distribution of acetaminophen in human brain. a</bold>) The human physiologically-based pharmacokinetic model which equals the rat physiologically-based pharmacokinetic model, but includes human instead of rat physiological parameters. (For the denotations in the model see Figure&#160;<xref ref-type="fig" rid="F4">4</xref>b). <bold>b</bold>) Acetaminophen concentrations in human plasma and brain. Data points represent observed data in human for plasma (black diamonds) and lumbar CSF (orange circles) by Bannwarth <italic toggle="yes">et al.</italic>[<xref ref-type="bibr" rid="B137">137</xref>]. Lines represent predictions of human plasma concentrations (black line), human lumbar CSF concentrations (orange line, and human brain ECF concentrations (blue line) by the &#8220;humanized&#8221; preclinical physiologically-based PK model [<xref ref-type="bibr" rid="B135">135</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2045-8118-10-12-5.jpg"/></fig><p>&#8226;Quinidine:</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Values of rat and human physiological parameters</p></caption><table frame="hsides" rules="groups" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="top"><tr><th align="left" colspan="1" rowspan="1"><bold>Physiological parameter</bold></th><th align="left" colspan="1" rowspan="1"><bold>Rat value</bold></th><th align="left" colspan="1" rowspan="1"><bold>Human value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom" colspan="1" rowspan="1">Brain ECF volume<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">290&#160;&#956;l<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">240&#160;ml<hr/></td></tr><tr><td align="left" valign="bottom" colspan="1" rowspan="1">Total CSF volume<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">300&#160;&#956;l<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">140&#160;ml<hr/></td></tr><tr><td align="left" valign="bottom" colspan="1" rowspan="1">Brain ECF flow<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">0.2&#160;&#956;l/min<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">0.2&#160;ml/min<hr/></td></tr><tr><td align="left" valign="bottom" colspan="1" rowspan="1">CSF flow<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">2.2&#160;&#956;l/min<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">0.4&#160;ml/min<hr/></td></tr><tr><td align="left" valign="bottom" colspan="1" rowspan="1">Lateral ventricle volume<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">50&#160;&#956;l<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">25&#160;ml<hr/></td></tr><tr><td align="left" valign="bottom" colspan="1" rowspan="1">Cisterna magna volume<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">17&#160;&#956;l<hr/></td><td align="left" valign="bottom" colspan="1" rowspan="1">7.5&#160;ml<hr/></td></tr><tr><td align="left" colspan="1" rowspan="1">Subarachnoid space volume</td><td align="left" colspan="1" rowspan="1">180&#160;&#956;l</td><td align="left" colspan="1" rowspan="1">90&#160;ml</td></tr></tbody></table></table-wrap><p>The same experimental setup was used for quinidine, a paradigm lipophilic compound and P-gp substrate. To investigate the specific contribution of P-gp-mediated transport, quinidine was administered at two different intravenous dosages, both with and without co-administration of tariquidar as P-gp transport inhibitor [Westerhout J, Smeets J, Danhof M, De Lange ECM: The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokin Pharmacodyn, submitted]. Figure&#160;<xref ref-type="fig" rid="F6">6</xref> shows the resulting kinetics of unbound quinidine in plasma, brain ECF, lateral ventricle CSF and cisterna magna CSF. Apart from the unexpected finding that brain ECF concentrations of quinidine were higher than the unbound quinidine concentrations in plasma (indicating an active influx that has not been identified before), substantial <italic toggle="yes">lower</italic> concentrations in brain ECF (striatum) compared to lateral ventricle and cisterna magna CSF were found for both the 10 and 20 mg/kg dose (Figure&#160;<xref ref-type="fig" rid="F6">6</xref> a,b). Upon co-administration of tariquidar, plasma concentrations remained similar, while brain concentrations for all compartments were substantially increased. Interestingly, now the brain ECF (striatum) concentrations were <italic toggle="yes">higher</italic> than those in the CSF compartments (Figure&#160;<xref ref-type="fig" rid="F6">6</xref> c,d). These data clearly show that the relationship between brain ECF and CSF concentrations is influenced by P-gp-mediated transport. It underscores the importance for more mechanistic insights into the processes that govern CNS drug concentrations at different sites in the brain.</p><fig id="F6" position="float" orientation="portrait"><label>Figure 6</label><caption><p><bold>Brain distribution of quinidine in the rat [Westerhout J, Smeets J, Danhof M, De Lange ECM: The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokin Pharmacodyn, submitted]</bold>. Average (geometric mean &#177;SEM) unbound quinidine concentration-time profiles following: <bold>a</bold>) 10 mg/kg, with co-administration of vehicle (-); <bold>b</bold>) 20 mg/kg, with co-administration of vehicle (-); <bold>c</bold>) 10 mg/kg with co-administration of 15 mg/kg tariquidar (+), and <bold>d</bold>) 20 mg/kg with co-administration of 15 mg/kg tariquidar (+). Black, blue, green and red symbols represent plasma, brain ECF, lateral ventricle CSF and cisterna magna CSF, respectively. Open symbols indicate data obtained without (-) and closed symbols represent data obtained with (+) the P-gp blocker tariquidar, respectively. The data show substantially <italic toggle="yes">lower</italic> concentrations in brain ECF (striatum) compared to lateral ventricle and cisterna magna CSF concentrations for both the 10 and 20 mg/kg dose (<bold>a</bold>, <bold>b</bold>). Upon co-administration of tariquidar, the brain ECF (striatum) concentrations were <italic toggle="yes">higher</italic> than those in the CSF compartments (<bold>c</bold>, <bold>d</bold>). These data show that the relationship between brain ECF and CSF concentrations is influenced by P-gp-mediated transport.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2045-8118-10-12-6.jpg"/></fig></sec><sec><title>Impact of route of administration on brain target site kinetics and CNS effects</title><p>The effects of therapeutic agents following oral administration are often limited due to active first-pass clearance by the liver and restricted BBB transport. Apart from rapid uptake of compounds from the systemic circulation, intranasal administration may provide the only direct route for non-invasive delivery of therapeutics into the CNS [<xref ref-type="bibr" rid="B138">138</xref>-<xref ref-type="bibr" rid="B140">140</xref>]. Intranasal administration could enhance the CNS target site bioavailability and therewith provide a more selective effect of CNS drugs [<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B141">141</xref>,<xref ref-type="bibr" rid="B142">142</xref>]. However, the immediate need is for quantitative information on both the rate and extent of delivery in relation to the action of nasally-administered drugs.</p><p>&#8226;Advanced mathematical PK model on remoxipride distribution in brain:</p><p>The recently-developed minimum-stress and freely-moving rat model for intranasal drug administration [<xref ref-type="bibr" rid="B143">143</xref>], was used together with serial sampling of plasma and brain microdialysate. The dopamine D2 receptor antagonist, remoxipride, was administered at three different doses via the intranasal or intravenous route. An advanced pharmacokinetic model was developed using the data obtained after intravenous dosing. For good prediction of the intranasal data, the model had to be extended with two absorption compartments, one for absorption from the nose into the systemic circulation, and one for absorption from the nose direct to the brain. The final model gave a good prediction on all observed data [<xref ref-type="bibr" rid="B144">144</xref>]. Figure&#160;<xref ref-type="fig" rid="F7">7</xref> shows the actual observed data points for plasma and brain ECF concentrations in the rat following intranasal and intravenous administration of remoxipride (open circles). In addition, in Figure&#160;<xref ref-type="fig" rid="F7">7</xref> the results of the so called &#8220;visual predictive check (VPC)&#8221; are displayed, as the prediction of the median concentration predictions of the model (black line), and the 90% prediction intervals (grey area). The VPC indicated that the model well described the observed data.</p><fig id="F7" position="float" orientation="portrait"><label>Figure 7</label><caption><p><bold>Brain distribution of remoxipride (REM) in the rat following intravenous (IV) and intranasal (IN) administration.</bold> Observed data points for plasma and brain ECF concentrations in the rat following intranasal and intravenous administration of remoxipride (open circles), and the &#8220;visual predictive check (VPC)&#8221; of the median concentration predictions of the model (black line), and the 90% prediction intervals (grey area). The VPC indicated that the model adequately described the observed data (from [<xref ref-type="bibr" rid="B147">147</xref>] with permission).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2045-8118-10-12-7.jpg"/></fig><p>The absorption process could be described in terms of rates and extent (bioavailability). About 75% of the intranasal dose was directly absorbed into the brain. Unexpectedly, the direct nose-to-brain absorption did not turn out to be a rapid route <italic toggle="yes">per se</italic>. For remoxipride, the rate was slow, explaining prolonged brain ECF exposure after intranasal compared to intravenous administration. This is the first time that both rate and extent of delivery have been identified quantitatively and is of utmost importance for optimizing direct nose-to-brain delivery, by varying drug properties and formulation [<xref ref-type="bibr" rid="B144">144</xref>].</p><p>&#8226;Advanced mathematical PK-PD model on remoxipride brain distribution and effects:</p><p>The advanced pharmacokinetic model on remoxipride brain distribution following intranasal and intravenous dosing was further developed to a PK-PD model. To that end, the plasma levels of the pituitary hormone prolactin, obtained in the same rats, were used as a biomarker of D2 receptor antagonism [<xref ref-type="bibr" rid="B145">145</xref>-<xref ref-type="bibr" rid="B147">147</xref>]. Furthermore, baseline variations in plasma prolactin concentrations were investigated [<xref ref-type="bibr" rid="B148">148</xref>]. Also, the prolactin response was measured following double low dosing of remoxipride at different time intervals to get information on the synthesis of prolactin in the pituitary lactotrophs [<xref ref-type="bibr" rid="B149">149</xref>,<xref ref-type="bibr" rid="B150">150</xref>]. The final PK-PD model consisted of 1) a pharmacokinetic model for plasma and unbound brain remoxipride concentrations, 2) a pool model for prolactin synthesis and storage, and its release into- and elimination from plasma, 3) a positive feedback of prolactin plasma concentrations on prolactin synthesis, and 4) the brain unbound concentrations of remoxipride for the inhibition of the D2 receptor, and resulting stimulation of prolactin release into plasma.</p><p>In conclusion, this mastermind approach allowed the explicit separation and quantitation of systemic and direct nose-to-brain transport after intranasal administration of remoxipride in the rat, and showed that the brain unbound concentrations could be directly linked to the effect. The model included parameters for the underlying processes of synthesis, storage and release of the pituitary hormone, and the positive feedback of its synthesis by prolactin plasma levels. The latter was in contradiction to a previous report [<xref ref-type="bibr" rid="B148">148</xref>]. An important finding was that indeed the brain unbound remoxipride concentrations were indistinguishable from target site concentrations to drive the release of prolactin into plasma. Such mechanistic information should be useful to extrapolate/predict the effects of remoxipride in humans.</p></sec><sec><title>Prediction of human target site kinetics and associated drug effects</title><p>Quantification of drug- and biological system specific parameters in translational mathematical models provides the opportunity to re-scale the animal model up to humans [<xref ref-type="bibr" rid="B129">129</xref>-<xref ref-type="bibr" rid="B131">131</xref>,<xref ref-type="bibr" rid="B151">151</xref>-<xref ref-type="bibr" rid="B153">153</xref>]. Allometric scaling of drug pharmacokinetic properties and the biological system-specific parameters have been used in previous translational investigations to predict drug effects in humans with a reasonable degree of success, [<xref ref-type="bibr" rid="B154">154</xref>,<xref ref-type="bibr" rid="B155">155</xref>]. Compared to pharmacokinetic properties, pharmacodynamic properties are more difficult to scale [<xref ref-type="bibr" rid="B156">156</xref>], since they are not often related to bodyweight (e.g. receptor occupancy, transduction, maximal effect, etc.). However, this information can be obtained from <italic toggle="yes">in vitro</italic> bioassays [<xref ref-type="bibr" rid="B157">157</xref>]. For many drugs and endogenous compounds, clinical information is readily available in literature [<xref ref-type="bibr" rid="B158">158</xref>-<xref ref-type="bibr" rid="B161">161</xref>]. This provides the opportunity to replace rat biological system parameters by human values, and to provide an extrapolation step from rat to human. At an early stage in drug development, such information can be used for simulation and to provide preliminary insight on the clinical applicability of a drug.</p><p>To test the predictive value of the preclinical PK-PD model of remoxipride [<xref ref-type="bibr" rid="B144">144</xref>,<xref ref-type="bibr" rid="B147">147</xref>], allometric scaling and literature data [<xref ref-type="bibr" rid="B162">162</xref>] were used to tune the preclinical PK-PD model, from rat systems to that of human [<xref ref-type="bibr" rid="B147">147</xref>]. Human data on remoxipride and prolactin plasma concentrations were used, being obtained following double intravenous administration of remoxipride at different time intervals [<xref ref-type="bibr" rid="B149">149</xref>]. The translational PK-PD model successfully predicted the remoxipride plasma kinetics in humans (Figure&#160;<xref ref-type="fig" rid="F8">8</xref>) as well as system prolactin response in humans, indicating that positive feedback on prolactin synthesis and allometric scaling thereof could be a new feature in describing complex homeostatic processes [<xref ref-type="bibr" rid="B147">147</xref>].</p><fig id="F8" position="float" orientation="portrait"><label>Figure 8</label><caption><p><bold>Observed and model prediction of remoxipride concentrations in human plasma (from</bold> [148,151,165] <bold>with permission).</bold> Human data on remoxipride and prolactin plasma concentrations were obtained following double intravenous administration of remoxipride at different time intervals. Data points on remoxipride concentrations in plasma (y-axis, concentration of remoxipride in &#956;mol/L) as a function of time (x-axis, time in hours) are presented for each individual human subject (open symbols, DV). Using allometric scaling the preclinical PK model of remoxipride was tuned to the human PK model. The human PK model successfully predicted the remoxipride plasma kinetics in humans: the individual prediction of the median remoxipride concentrations is indicated (IPRE, <sup>________</sup>) as well as the population prediction (PRED, ---------).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2045-8118-10-12-8.jpg"/></fig></sec></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Drug properties and biological system properties together determine intracerebral distribution of drugs and subsequent CNS effects. The fact that rate as well as extent of the biological processes are dynamically regulated and therefore may be condition dependent, explains the high intra and inter-individual variability encountered in CNS drug effects. We also need to understand the sources of variability in CNS drug effects to be able to improve drug development and therapies. Moreover, as these processes are working concurrently, and together determine the final CNS effect, they cannot only be studied in isolation, indicating the need for integrated <italic toggle="yes">in vivo</italic> experiments.</p><p>In these experiments data on plasma PK, brain distribution and CNS effects of a drug should be obtained from the same setting as much as possible. In addition, time-dependency should be explicitly included, and information should be obtained on the unbound drug. Then, the contribution of a certain process in the PK-PD relationship can be deduced, either by changing experimental conditions in a controlled manner (e.g. blocking of an active transport process, or irreversible binding of part of particular receptors), or by performing the same experiment for a different drug, and the use of advanced mathematical modeling. This approach is here introduced as the &#8220;Mastermind approach&#8221;. Examples given of this approach show that data from preclinical translational models in principle are able to predict human CNS drug distribution, target site kinetics, and CNS drug effects.</p></sec><sec><title>Abbreviations</title><p>BBB: Blood&#8211;brain barrier;BCSFB: Blood-CSF-barrier;Brain ECF: Brain extracellular fluid;CNS: Central nervous system;CSF: Cerebrospinal fluid;ECF: Extracellular fluid;P-gp: P-glycoprotein</p></sec><sec><title>Competing interests</title><p>The author declare that She have no Competing Interest</p></sec><sec><title>Author&#8217;s contribution</title><p>EL had the overall supervision on the data generation and modelling, and performed the writing of the manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>The author would like to acknowledge Joost Westerhout, Jasper Stevens and Paulien Ravenstijn for performing animal experiments and data modeling, Ernst Suidgeest and Robin Hartman for performing surgery and help with animal experimentation, Dirk-Jan vd Berg for performing sample concentration analysis, Bart Ploeger, Jean Smeets, and Henk-Jan Drenth for support in data modeling, and Kristel van Belle, Piet Hein vd Graaf and Meindert Danhof for their contribution in discussions on overall design of the studies. In addition, the author would like to acknowledge Eli Lilly for the grant on the Parkinson&#8217;s disease studies, Pfizer for the grant for the Remoxipride studies, Margareta Hammarlund-Udenaes for providing human data on remoxipride and prolactine, and the Top Institute Pharma (project T5-105-1) for the grant for the brain distribution studies.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="other"><collab>World Health Organization</collab><source>&#8220;Neurological Disorders: Public Health Challenges&#8221;</source><year>2007</year></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name name-style="western"><surname>Neuwelt</surname><given-names>EA</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Abrey</surname><given-names>L</given-names></name><name name-style="western"><surname>Banks</surname><given-names>WA</given-names></name><name name-style="western"><surname>Blakley</surname><given-names>B</given-names></name><name name-style="western"><surname>Davis</surname><given-names>T</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>B</given-names></name><name name-style="western"><surname>Grammas</surname><given-names>P</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name><name name-style="western"><surname>Nutt</surname><given-names>J</given-names></name><name name-style="western"><surname>Pardridge</surname><given-names>W</given-names></name><name name-style="western"><surname>Rosenburg</surname><given-names>GA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>Q</given-names></name><name name-style="western"><surname>Drewes</surname><given-names>LR</given-names></name><article-title>Strategies to advance translational research into brain barriers</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><fpage>84</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(07)70326-5</pub-id><pub-id pub-id-type="pmid">18093565</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name name-style="western"><surname>Pardridge</surname><given-names>WM</given-names></name><article-title>Blood&#8211;brain barrier delivery</article-title><source>Drug Disc Today</source><year>2007</year><volume>12</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2006.10.013</pub-id><pub-id pub-id-type="pmid">17198973</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name name-style="western"><surname>Jeffrey</surname><given-names>P</given-names></name><name name-style="western"><surname>Summerfield</surname><given-names>S</given-names></name><article-title>Assessment of the blood&#8211;brain barrier in CNS drug discovery</article-title><source>Neurobiol Dis</source><year>2010</year><volume>37</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2009.07.033</pub-id><pub-id pub-id-type="pmid">19664709</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name name-style="western"><surname>De Lange</surname><given-names>ECM</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><article-title>Considerations in the use of cerebrospinal fluid pharmacokinetic to predict brain target concentrations in the clinical setting. Implications of the barriers between blood and brain</article-title><source>Clin Pharmacokinet</source><year>2002</year><volume>41</volume><fpage>691</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.2165/00003088-200241100-00001</pub-id><pub-id pub-id-type="pmid">12162757</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><name name-style="western"><surname>Frid&#233;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Syv&#228;nen</surname><given-names>S</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><article-title>On the rate and extent of drug delivery to the brain</article-title><source>Pharm Res</source><year>2008</year><volume>25</volume><fpage>1737</fpage><lpage>1750</lpage><pub-id pub-id-type="doi">10.1007/s11095-007-9502-2</pub-id><pub-id pub-id-type="pmid">18058202</pub-id><pub-id pub-id-type="pmcid">PMC2469271</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name name-style="western"><surname>Syv&#228;nen</surname><given-names>S</given-names></name><name name-style="western"><surname>Lindhe</surname><given-names>O</given-names></name><name name-style="western"><surname>Palner</surname><given-names>M</given-names></name><name name-style="western"><surname>Kornum</surname><given-names>BR</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>O</given-names></name><name name-style="western"><surname>L&#229;ngstr&#246;m</surname><given-names>B</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>GM</given-names></name><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><article-title>Species differences in blood&#8211;brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport</article-title><source>Drug Metab Dispos</source><year>2009</year><volume>37</volume><fpage>635</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.024745</pub-id><pub-id pub-id-type="pmid">19047468</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name name-style="western"><surname>Eyal</surname><given-names>S</given-names></name><name name-style="western"><surname>Ke</surname><given-names>B</given-names></name><name name-style="western"><surname>Muzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Link</surname><given-names>JM</given-names></name><name name-style="western"><surname>Mankoff</surname><given-names>DA</given-names></name><name name-style="western"><surname>Collier</surname><given-names>AC</given-names></name><name name-style="western"><surname>Unadkat</surname><given-names>JD</given-names></name><article-title>Regional P-glycoprotein activity and inhibition at the human blood&#8211;brain barrier as imaged by positron emission tomography</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>87</volume><fpage>579</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1038/clpt.2010.11</pub-id><pub-id pub-id-type="pmid">20336065</pub-id><pub-id pub-id-type="pmcid">PMC2939015</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name name-style="western"><surname>DeLorenzo</surname><given-names>C</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>JS</given-names></name><name name-style="western"><surname>Mann</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Parsey</surname><given-names>RV</given-names></name><article-title>In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688</article-title><source>J Cereb Blood Flow Metab</source><year>2011</year><volume>31</volume><fpage>2169</fpage><lpage>2180</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2011.105</pub-id><pub-id pub-id-type="pmid">21792244</pub-id><pub-id pub-id-type="pmcid">PMC3210337</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bra&#353;i&#263;</surname><given-names>JR</given-names></name><name name-style="western"><surname>Cascella</surname><given-names>N</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hilton</surname><given-names>J</given-names></name><name name-style="western"><surname>Raymont</surname><given-names>V</given-names></name><name name-style="western"><surname>Crabb</surname><given-names>A</given-names></name><name name-style="western"><surname>Guevara</surname><given-names>MR</given-names></name><name name-style="western"><surname>Horti</surname><given-names>AG</given-names></name><name name-style="western"><surname>Wong</surname><given-names>DF</given-names></name><article-title>Positron emission tomography experience with 2-[18&#160;F]fluoro-3-(2(S)-azetidinyl-methoxy)-pyridine (2-[18&#160;F]FA) in the living human brain of smokers with paranoid schizophrenia</article-title><source>Synapse</source><year>2012</year><volume>66</volume><fpage>352</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1002/syn.21520</pub-id><pub-id pub-id-type="pmid">22169936</pub-id><pub-id pub-id-type="pmcid">PMC3445266</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name name-style="western"><surname>Atlas</surname><given-names>LY</given-names></name><name name-style="western"><surname>Whittington</surname><given-names>RA</given-names></name><name name-style="western"><surname>Lindquist</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wielgosz</surname><given-names>J</given-names></name><name name-style="western"><surname>Sonty</surname><given-names>N</given-names></name><name name-style="western"><surname>Wager</surname><given-names>TD</given-names></name><article-title>Dissociable influences of opiates and expectations on pain</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>8053</fpage><lpage>8064</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0383-12.2012</pub-id><pub-id pub-id-type="pmid">22674280</pub-id><pub-id pub-id-type="pmcid">PMC3387557</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name name-style="western"><surname>Upadhyay</surname><given-names>J</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>R</given-names></name><name name-style="western"><surname>Coimbra</surname><given-names>A</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Pendse</surname><given-names>G</given-names></name><name name-style="western"><surname>Wallin</surname><given-names>D</given-names></name><name name-style="western"><surname>Nutile</surname><given-names>L</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>J</given-names></name><name name-style="western"><surname>George</surname><given-names>E</given-names></name><name name-style="western"><surname>Elman</surname><given-names>I</given-names></name><name name-style="western"><surname>Sunkaraneni</surname><given-names>S</given-names></name><name name-style="western"><surname>Maier</surname><given-names>G</given-names></name><name name-style="western"><surname>Iyengar</surname><given-names>S</given-names></name><name name-style="western"><surname>Evelhoch</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bleakman</surname><given-names>D</given-names></name><name name-style="western"><surname>Hargreaves</surname><given-names>R</given-names></name><name name-style="western"><surname>Becerra</surname><given-names>L</given-names></name><name name-style="western"><surname>Borsook</surname><given-names>D</given-names></name><article-title>Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine</article-title><source>Neuroimage</source><year>2012</year><volume>59</volume><fpage>3762</fpage><lpage>3773</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.11.034</pub-id><pub-id pub-id-type="pmid">22119647</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bruce</surname><given-names>JN</given-names></name><name name-style="western"><surname>Oldfield</surname><given-names>EH</given-names></name><article-title>Method for sequential sampling of cerebrospinal fluid in humans</article-title><source>Neurosurgery</source><year>1988</year><volume>23</volume><fpage>788</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1227/00006123-198812000-00024</pub-id><pub-id pub-id-type="pmid">3216983</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lin</surname><given-names>JH</given-names></name><article-title>CSF as a surrogate for assessing CNS exposure: An industrial perspective</article-title><source>Curr Drug Metab</source><year>2008</year><volume>9</volume><fpage>46</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.2174/138920008783331077</pub-id><pub-id pub-id-type="pmid">18220571</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Van Natta</surname><given-names>K</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>H</given-names></name><name name-style="western"><surname>Vilenski</surname><given-names>O</given-names></name><name name-style="western"><surname>Weller</surname><given-names>PE</given-names></name><name name-style="western"><surname>Worboys</surname><given-names>PD</given-names></name><name name-style="western"><surname>Monshouwer</surname><given-names>M</given-names></name><article-title>Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid</article-title><source>Drug Metab Dispos</source><year>2009</year><volume>37</volume><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.024125</pub-id><pub-id pub-id-type="pmid">19116265</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name name-style="western"><surname>Frid&#233;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Winiwarter</surname><given-names>S</given-names></name><name name-style="western"><surname>Jerndal</surname><given-names>G</given-names></name><name name-style="western"><surname>Bengtsson</surname><given-names>O</given-names></name><name name-style="western"><surname>Wan</surname><given-names>H</given-names></name><name name-style="western"><surname>Bredberg</surname><given-names>U</given-names></name><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><name name-style="western"><surname>Antonsson</surname><given-names>M</given-names></name><article-title>Structure&#8212;Brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids</article-title><source>J Med Chem</source><year>2009</year><volume>52</volume><fpage>6233</fpage><lpage>6243</lpage><pub-id pub-id-type="doi">10.1021/jm901036q</pub-id><pub-id pub-id-type="pmid">19764786</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name name-style="western"><surname>Westerhout</surname><given-names>J</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><article-title>Preclinical prediction of human brain target site concentrations: Considerations in extrapolating to the clinical setting</article-title><source>J Pharm Sci</source><year>2011</year><volume>100</volume><fpage>3577</fpage><lpage>3593</lpage><pub-id pub-id-type="doi">10.1002/jps.22604</pub-id><pub-id pub-id-type="pmid">21544824</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name name-style="western"><surname>De Lange</surname><given-names>ECM</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>De Boer</surname><given-names>AG</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>DD</given-names></name><article-title>Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on blood&#8211;brain barrier transport of drugs</article-title><source>Brain Res Rev</source><year>1997</year><volume>25</volume><fpage>27</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/S0165-0173(97)00014-3</pub-id><pub-id pub-id-type="pmid">9370049</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name name-style="western"><surname>Hillered</surname><given-names>L</given-names></name><name name-style="western"><surname>Persson</surname><given-names>L</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>P</given-names></name><name name-style="western"><surname>Ronne-Engstrom</surname><given-names>E</given-names></name><name name-style="western"><surname>Enblad</surname><given-names>P</given-names></name><article-title>Continuous monitoring of cerebral metabolism in traumatic brain injury: a focus on cerebral microdialysis</article-title><source>Curr Opin Crit Care</source><year>2006</year><volume>12</volume><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1097/01.ccx.0000216576.11439.df</pub-id><pub-id pub-id-type="pmid">16543785</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ederoth</surname><given-names>P</given-names></name><name name-style="western"><surname>Tunblad</surname><given-names>K</given-names></name><name name-style="western"><surname>Bouw</surname><given-names>R</given-names></name><name name-style="western"><surname>Lundberg</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ungerstedt</surname><given-names>U</given-names></name><name name-style="western"><surname>Nordstr&#246;m</surname><given-names>CH</given-names></name><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><article-title>Blood&#8211;brain barrier transport of morphine in patients with severe brain trauma</article-title><source>Br J Clin Pharmacol</source><year>2004</year><volume>57</volume><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.02032.x</pub-id><pub-id pub-id-type="pmid">15025740</pub-id><pub-id pub-id-type="pmcid">PMC1884477</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name name-style="western"><surname>Fenstermacher</surname><given-names>JD</given-names></name><name name-style="western"><surname>Patlak</surname><given-names>CS</given-names></name><name name-style="western"><surname>Blasberg</surname><given-names>RG</given-names></name><article-title>Transport of material between brain extracellular fluid, brain cells and blood</article-title><source>Fed Proc</source><year>1974</year><volume>33</volume><fpage>2070</fpage><lpage>2074</lpage><pub-id pub-id-type="pmid">4214378</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name name-style="western"><surname>Collins</surname><given-names>JM</given-names></name><name name-style="western"><surname>Dedrick</surname><given-names>LD</given-names></name><article-title>Distributed model for drug delivery to CSF and brain tissue</article-title><source>J Am Physiol</source><year>1983</year><volume>14</volume><fpage>R303</fpage><lpage>R310</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpregu.1983.245.3.R303</pub-id><pub-id pub-id-type="pmid">6614201</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name name-style="western"><surname>Davson</surname><given-names>H</given-names></name><name name-style="western"><surname>Oldendorf</surname><given-names>WH</given-names></name><article-title>Transport in the central nervous system</article-title><source>Proc R Soc Med</source><year>1967</year><volume>60</volume><fpage>326</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">6021942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/003591576706000405</pub-id><pub-id pub-id-type="pmcid">PMC1901728</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bodor</surname><given-names>N</given-names></name><name name-style="western"><surname>Brewster</surname><given-names>ME</given-names></name><article-title>Problems of drug delivery of drugs to the brain</article-title><source>Pharmacol Ther</source><year>1982</year><volume>19</volume><fpage>337</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/0163-7258(82)90073-0</pub-id><pub-id pub-id-type="pmid">6765182</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name name-style="western"><surname>Segal</surname><given-names>MB</given-names></name><article-title>Extracellular and cerebrospinal fluids</article-title><source>J Inher Metab Dis</source><year>1993</year><volume>16</volume><fpage>617</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1007/BF00711896</pub-id><pub-id pub-id-type="pmid">8412010</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name name-style="western"><surname>Betz</surname><given-names>AL</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>GW</given-names></name><article-title>Specialized properties and solute transport in brain capillaries</article-title><source>Annu Rev Physiol</source><year>1986</year><volume>48</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1146/annurev.ph.48.030186.001325</pub-id><pub-id pub-id-type="pmid">2871806</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mayer</surname><given-names>S</given-names></name><name name-style="western"><surname>Maickel</surname><given-names>RP</given-names></name><name name-style="western"><surname>Brodie</surname><given-names>BB</given-names></name><article-title>Kinetics of penetration of drugs and other foreign compounds into cerebrospinal fluid and brain</article-title><source>J Pharmacol Exp Ther</source><year>1959</year><volume>127</volume><fpage>205</fpage><lpage>211</lpage></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name name-style="western"><surname>Oldendorf</surname><given-names>WH</given-names></name><article-title>Lipid solubility and drug penetration of the blood&#8211;brain barrier</article-title><source>Proc Soc Exp Biol Med</source><year>1974</year><volume>174</volume><fpage>813</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">4445171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3181/00379727-147-38444</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name name-style="western"><surname>Keep</surname><given-names>RF</given-names></name><name name-style="western"><surname>Jones</surname><given-names>HC</given-names></name><article-title>A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat</article-title><source>Dev Brain Res</source><year>1990</year><volume>56</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/0165-3806(90)90163-S</pub-id><pub-id pub-id-type="pmid">2279331</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>Alvan</surname><given-names>G</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>SG</given-names></name><name name-style="western"><surname>Kuhlmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Paintaud</surname><given-names>G</given-names></name><article-title>Mechanism-based pharmacokinetic-pharmacodynamic modelling &#8211; a new classification of biomarkers</article-title><source>Pharm Res</source><year>2005</year><volume>22</volume><fpage>1432</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1007/s11095-005-5882-3</pub-id><pub-id pub-id-type="pmid">16132354</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Jongh</surname><given-names>J</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><name name-style="western"><surname>Della Pasqua</surname><given-names>OE</given-names></name><name name-style="western"><surname>Ploeger</surname><given-names>BA</given-names></name><name name-style="western"><surname>Voskuyl</surname><given-names>RA</given-names></name><article-title>Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2007</year><volume>47</volume><fpage>357</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.47.120505.105154</pub-id><pub-id pub-id-type="pmid">17067280</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name><article-title>Role of efflux transport across the blood&#8211;brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system</article-title><source>Adv Drug Del Rev</source><year>1997</year><volume>25</volume><fpage>257</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(97)00503-6</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name name-style="western"><surname>Urien</surname><given-names>S</given-names></name><name name-style="western"><surname>Pinquier</surname><given-names>JL</given-names></name><name name-style="western"><surname>Paquette</surname><given-names>B</given-names></name><name name-style="western"><surname>Chaumet</surname><given-names>RP</given-names></name><name name-style="western"><surname>Kiechel</surname><given-names>JR</given-names></name><name name-style="western"><surname>Tillement</surname><given-names>JP</given-names></name><article-title>Effect of the binding of isradipine and darodipine to different plasma proteins on their transfer through the blood&#8211;brain barrier</article-title><source>J Pharmacol Exp Ther</source><year>1987</year><volume>242</volume><fpage>349</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">2956411</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name name-style="western"><surname>Jolliet</surname><given-names>P</given-names></name><name name-style="western"><surname>Simon</surname><given-names>N</given-names></name><name name-style="western"><surname>Bree</surname><given-names>F</given-names></name><name name-style="western"><surname>Urien</surname><given-names>S</given-names></name><name name-style="western"><surname>Pagliara</surname><given-names>A</given-names></name><name name-style="western"><surname>Carrupt</surname><given-names>P-A</given-names></name><name name-style="western"><surname>Testa</surname><given-names>B</given-names></name><name name-style="western"><surname>Tillement</surname><given-names>JP</given-names></name><article-title>Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery</article-title><source>Pharm Res</source><year>1997</year><volume>14</volume><fpage>650</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1023/A:1012165414610</pub-id><pub-id pub-id-type="pmid">9165538</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Mizojiri</surname><given-names>K</given-names></name><article-title>Drug-protein binding and blood&#8211;brain barrier permeability</article-title><source>J Pharmacol Exp Ther</source><year>1999</year><volume>288</volume><fpage>912</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">10027826</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mandula</surname><given-names>H</given-names></name><name name-style="western"><surname>Parepally</surname><given-names>JM</given-names></name><name name-style="western"><surname>Feng</surname><given-names>R</given-names></name><name name-style="western"><surname>Smith</surname><given-names>QR</given-names></name><article-title>Role of site-specific binding to plasma albumin in drug availability to brain</article-title><source>J Pharmacol Exp Ther</source><year>2006</year><volume>317</volume><fpage>667</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1124/jpet.105.097402</pub-id><pub-id pub-id-type="pmid">16410405</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name name-style="western"><surname>Schmidt</surname><given-names>S</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>D</given-names></name><name name-style="western"><surname>Derendorf</surname><given-names>H</given-names></name><article-title>Significance of protein binding in pharmacokinetics and pharmacodynamics</article-title><source>J Pharm Sci</source><year>2010</year><volume>99</volume><fpage>1107</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1002/jps.21916</pub-id><pub-id pub-id-type="pmid">19852037</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name name-style="western"><surname>Summerfield</surname><given-names>SG</given-names></name><name name-style="western"><surname>Jeffrey</surname><given-names>P</given-names></name><article-title><italic toggle="yes">In vitro</italic> prediction of brain penetration &#8211; a case for unbound thinking?</article-title><source>Expert Opin Drug Discov</source><year>2006</year><volume>1</volume><fpage>595</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1517/17460441.1.6.595</pub-id><pub-id pub-id-type="pmid">23506069</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name name-style="western"><surname>Watson</surname><given-names>J</given-names></name><name name-style="western"><surname>Wright</surname><given-names>S</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>A</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>KL</given-names></name><name name-style="western"><surname>Viggers</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheetham</surname><given-names>S</given-names></name><name name-style="western"><surname>Jeffrey</surname><given-names>P</given-names></name><name name-style="western"><surname>Porter</surname><given-names>R</given-names></name><name name-style="western"><surname>Read</surname><given-names>KD</given-names></name><article-title>Receptor occupancy and brain unbound fraction</article-title><source>Drug Metab Dispos</source><year>2009</year><volume>37</volume><fpage>753</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.022814</pub-id><pub-id pub-id-type="pmid">19158315</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name name-style="western"><surname>Abbott</surname><given-names>NJ</given-names></name><name name-style="western"><surname>R&#246;nnb&#228;ck</surname><given-names>L</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>E</given-names></name><article-title>Astrocyte-endothelial interactions at the blood&#8211;brain barrier</article-title><source>Nat Rev Neurosci</source><year>2006</year><volume>7</volume><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/nrn1824</pub-id><pub-id pub-id-type="pmid">16371949</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bernacki</surname><given-names>J</given-names></name><name name-style="western"><surname>Dobrowolska</surname><given-names>A</given-names></name><name name-style="western"><surname>Nierwi&#324;ska</surname><given-names>K</given-names></name><name name-style="western"><surname>Ma&#322;ecki</surname><given-names>A</given-names></name><article-title>Physiology and pharmacological role of the blood&#8211;brain barrier</article-title><source>Pharmacol Rep</source><year>2008</year><volume>60</volume><fpage>600</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">19066407</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="book"><name name-style="western"><surname>Cserr</surname><given-names>HF</given-names></name><person-group person-group-type="editor">Shapiro K, Marmarou A, Portnoy H</person-group><article-title>Convection of brain interstitial fluid</article-title><source>Hydrocephalus</source><year>1984</year><publisher-name>New York: Raven Press</publisher-name><fpage>59</fpage><lpage>68</lpage></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name name-style="western"><surname>Cserr</surname><given-names>HF</given-names></name><name name-style="western"><surname>Bundgaard</surname><given-names>M</given-names></name><article-title>Blood&#8211;brain interfaces in vertebrates: a comparative approach</article-title><source>Am J Physiol</source><year>1984</year><volume>246</volume><fpage>R277</fpage><lpage>R288</lpage><pub-id pub-id-type="pmid">6367490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpregu.1984.246.3.R277</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="book"><name name-style="western"><surname>Davson</surname><given-names>H</given-names></name><name name-style="western"><surname>Segal</surname><given-names>MB</given-names></name><source>Physiology of the CSF and blood&#8211;brain barriers</source><year>1996</year><publisher-name>Boca Raton, FL: CRC Press</publisher-name></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name name-style="western"><surname>Wijnholds</surname><given-names>J</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><name name-style="western"><surname>Scheffer</surname><given-names>GL</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>D-J</given-names></name><name name-style="western"><surname>Mol</surname><given-names>CAAM</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>M</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>AH</given-names></name><name name-style="western"><surname>Scheper</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>DD</given-names></name><name name-style="western"><surname>Borst</surname><given-names>P</given-names></name><article-title>Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier</article-title><source>J Clin Invest</source><year>2000</year><volume>105</volume><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1172/JCI8267</pub-id><pub-id pub-id-type="pmid">10675353</pub-id><pub-id pub-id-type="pmcid">PMC377447</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name name-style="western"><surname>Choudhuri</surname><given-names>S</given-names></name><name name-style="western"><surname>Cherrington</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Klaassen</surname><given-names>CD</given-names></name><article-title>Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats</article-title><source>Drug Metab Dispos</source><year>2003</year><volume>31</volume><fpage>1337</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1124/dmd.31.11.1337</pub-id><pub-id pub-id-type="pmid">14570765</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name name-style="western"><surname>De Lange</surname><given-names>ECM</given-names></name><article-title>Potential role of ABC transporters as a detoxification system at the blood-cerebrospinal fluid-barrier</article-title><source>Adv Drug Del Rev</source><year>2004</year><volume>56</volume><fpage>1793</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2004.07.009</pub-id><pub-id pub-id-type="pmid">15381334</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name name-style="western"><surname>Johanson</surname><given-names>CE</given-names></name><name name-style="western"><surname>Stopa</surname><given-names>EG</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>PN</given-names></name><article-title>The blood-cerebrospinal fluid barrier: structure and functional significance</article-title><source>Methods Mol Biol</source><year>2011</year><volume>686</volume><fpage>101</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1007/978-1-60761-938-3_4</pub-id><pub-id pub-id-type="pmid">21082368</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name name-style="western"><surname>Graff</surname><given-names>CL</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>G</given-names></name><article-title>Drug transport at the blood&#8211;brain barrier and the choroid plexus</article-title><source>Curr Drug Metab</source><year>2004</year><volume>5</volume><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.2174/1389200043489126</pub-id><pub-id pub-id-type="pmid">14965253</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name name-style="western"><surname>De Lange</surname><given-names>ECM</given-names></name><article-title>The physiological characteristics and transcytosis mechanisms of the blood&#8211;brain barrier</article-title><source>Curr Pharmaceutical Biotechnol</source><year>2012</year><volume>13</volume><fpage>2319</fpage><lpage>2327</lpage><pub-id pub-id-type="doi">10.2174/138920112803341860</pub-id><pub-id pub-id-type="pmid">23016638</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name name-style="western"><surname>Levin</surname><given-names>VA</given-names></name><article-title>Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability</article-title><source>J Med Chem</source><year>1980</year><volume>23</volume><fpage>682</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1021/jm00180a022</pub-id><pub-id pub-id-type="pmid">7392035</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name name-style="western"><surname>Greig</surname><given-names>NH</given-names></name><name name-style="western"><surname>Momma</surname><given-names>S</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Smith</surname><given-names>QR</given-names></name><name name-style="western"><surname>Rapoport</surname><given-names>SI</given-names></name><article-title>Facilitated transport of melphalan at the rat blood&#8211;brain barrier by the large neutral amino acid carrier system</article-title><source>Cancer Res</source><year>1987</year><volume>47</volume><fpage>1571</fpage><lpage>1576</lpage><pub-id pub-id-type="pmid">3815357</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name name-style="western"><surname>Tsuji</surname><given-names>A</given-names></name><name name-style="western"><surname>Tamai</surname><given-names>I</given-names></name><article-title>Carrier-mediated or specialized transport of drugs across the blood&#8211;brain barrier</article-title><source>Adv Drug Deliv Rev</source><year>1999</year><volume>36</volume><fpage>277</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(98)00084-2</pub-id><pub-id pub-id-type="pmid">10837720</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name name-style="western"><surname>Gjedde</surname><given-names>A</given-names></name><name name-style="western"><surname>Crone</surname><given-names>C</given-names></name><article-title>Biochemical modulation of blood&#8211;brain barrier permeability</article-title><source>Acta Neuropathol Suppl</source><year>1983</year><volume>8</volume><fpage>59</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-68970-3_5</pub-id><pub-id pub-id-type="pmid">6346779</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name name-style="western"><surname>Guillot</surname><given-names>FL</given-names></name><name name-style="western"><surname>Audus</surname><given-names>KL</given-names></name><name name-style="western"><surname>Raub</surname><given-names>TJ</given-names></name><article-title>Fluid-phase endocytosis by primary cultures of bovine brain microvessel endothelial cell monolayers</article-title><source>Microvasc Res</source><year>1990</year><volume>39</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/0026-2862(90)90055-V</pub-id><pub-id pub-id-type="pmid">2314302</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name name-style="western"><surname>Gonatas</surname><given-names>JA</given-names></name><name name-style="western"><surname>Steiber</surname><given-names>S</given-names></name><name name-style="western"><surname>Olsnes</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gonatas</surname><given-names>NK</given-names></name><article-title>Pathways involved in fluid phase and adsorptive endocytosis in neuroblastoma</article-title><source>J Cell Biol</source><year>1980</year><volume>87</volume><fpage>3579</fpage><lpage>3588</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.87.3.579</pub-id><pub-id pub-id-type="pmcid">PMC2110778</pub-id><pub-id pub-id-type="pmid">7462317</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name name-style="western"><surname>Broadwell</surname><given-names>RD</given-names></name><article-title>Transcytosis of macromolecules through the blood&#8211;brain barrier: a cell biological perspective and critical appraisal</article-title><source>Acta Neuropathol Berlin</source><year>1989</year><volume>79</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1007/BF00294368</pub-id><pub-id pub-id-type="pmid">2688350</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name name-style="western"><surname>Tuma</surname><given-names>PL</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>AL</given-names></name><article-title>Transcytosis: crossing cellular barriers</article-title><source>Physiol Rev</source><year>2003</year><volume>83</volume><fpage>871</fpage><lpage>932</lpage><pub-id pub-id-type="pmid">12843411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00001.2003</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name name-style="western"><surname>Gonatas</surname><given-names>NK</given-names></name><name name-style="western"><surname>Stieber</surname><given-names>A</given-names></name><name name-style="western"><surname>Hickey</surname><given-names>WF</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>SH</given-names></name><name name-style="western"><surname>Gonatas</surname><given-names>JO</given-names></name><article-title>Endosomes and Golgi vesicles in adsorptive and fluid phase endocytosis</article-title><source>J Cell Biol</source><year>1984</year><volume>99</volume><fpage>1379</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1083/jcb.99.4.1379</pub-id><pub-id pub-id-type="pmid">6548223</pub-id><pub-id pub-id-type="pmcid">PMC2113314</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name name-style="western"><surname>Herv&#233;</surname><given-names>F</given-names></name><name name-style="western"><surname>Ghinea</surname><given-names>N</given-names></name><name name-style="western"><surname>Scherrmann</surname><given-names>JM</given-names></name><article-title>CNS delivery via adsorptive transcytosis</article-title><source>AAPS J</source><year>2008</year><volume>10</volume><fpage>455</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1208/s12248-008-9055-2</pub-id><pub-id pub-id-type="pmid">18726697</pub-id><pub-id pub-id-type="pmcid">PMC2761699</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name name-style="western"><surname>Pardridge</surname><given-names>WM</given-names></name><article-title>Receptor-mediated peptide transport through the blood&#8211;brain barrier</article-title><source>Endocrine Rev</source><year>1986</year><volume>7</volume><fpage>314</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1210/edrv-7-3-314</pub-id><pub-id pub-id-type="pmid">3017689</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name name-style="western"><surname>Giacomini</surname><given-names>KM</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S-M</given-names></name><name name-style="western"><surname>Tweedie</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>KLR</given-names></name><name name-style="western"><surname>Chu</surname><given-names>X</given-names></name><name name-style="western"><surname>Dahlin</surname><given-names>A</given-names></name><name name-style="western"><surname>Evers</surname><given-names>R</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>V</given-names></name><name name-style="western"><surname>Hillgren</surname><given-names>KM</given-names></name><name name-style="western"><surname>Hoffmaster</surname><given-names>KA</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Keppler</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>RB</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CA</given-names></name><name name-style="western"><surname>Niemi</surname><given-names>M</given-names></name><name name-style="western"><surname>Polli</surname><given-names>JW</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Swaan</surname><given-names>PW</given-names></name><name name-style="western"><surname>Ware</surname><given-names>JA</given-names></name><name name-style="western"><surname>Wright</surname><given-names>SH</given-names></name><name name-style="western"><surname>Wah Yee</surname><given-names>S</given-names></name><name name-style="western"><surname>Zamek-Gliszczyncski</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><article-title>Membrane transporters in drug development</article-title><source>Nat Rev Drug Discov</source><year>2010</year><volume>9</volume><fpage>215</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/nrd3028</pub-id><pub-id pub-id-type="pmid">20190787</pub-id><pub-id pub-id-type="pmcid">PMC3326076</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name name-style="western"><surname>Uchida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohtsuki</surname><given-names>S</given-names></name><name name-style="western"><surname>Katsukura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>C</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Kamiie</surname><given-names>J</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>T</given-names></name><article-title>Quantitative targeted absolute proteomics of human blood&#8211;brain barrier transporters and receptors</article-title><source>J Neurochem</source><year>2011</year><volume>117</volume><fpage>333</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07208.x</pub-id><pub-id pub-id-type="pmid">21291474</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name name-style="western"><surname>Begley</surname><given-names>DJ</given-names></name><article-title>ABC transporters and the blood&#8211;brain barrier</article-title><source>Curr Pharm Des</source><year>2004</year><volume>10</volume><fpage>1295</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.2174/1381612043384844</pub-id><pub-id pub-id-type="pmid">15134482</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name name-style="western"><surname>De Boer</surname><given-names>AG</given-names></name><name name-style="western"><surname>van der Sandt</surname><given-names>I</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>PJ</given-names></name><article-title>The role of drug transporters at the blood&#8211;brain barrier</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2003</year><volume>43</volume><fpage>629</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.43.100901.140204</pub-id><pub-id pub-id-type="pmid">12415123</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kusuhara</surname><given-names>H</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name><article-title>Efflux transport systems for organic anions and cations at the blood-CSF barrier</article-title><source>Adv Drug Del Rev</source><year>2004</year><volume>56</volume><fpage>1741</fpage><lpage>1763</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2004.07.007</pub-id><pub-id pub-id-type="pmid">15381332</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kusuhara</surname><given-names>H</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name><article-title>Active efflux across the blood&#8211;brain barrier: role of the solute carrier family</article-title><source>NeuroRx</source><year>2005</year><volume>2</volume><fpage>73</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1602/neurorx.2.1.73</pub-id><pub-id pub-id-type="pmid">15717059</pub-id><pub-id pub-id-type="pmcid">PMC539323</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>G</given-names></name><name name-style="western"><surname>Dallas</surname><given-names>S</given-names></name><name name-style="western"><surname>Hong</surname><given-names>M</given-names></name><name name-style="western"><surname>Bendayan</surname><given-names>R</given-names></name><article-title>Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations</article-title><source>Pharmacol Rev</source><year>2001</year><volume>53</volume><fpage>569</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">11734619</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><name name-style="western"><surname>L&#246;scher</surname><given-names>W</given-names></name><name name-style="western"><surname>Potschka</surname><given-names>H</given-names></name><article-title>Blood&#8211;brain barrier active efflux transporters: ATP-binding cassette gene family</article-title><source>Nat Rev Neurosci</source><year>2005</year><volume>6</volume><fpage>591</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">15717060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1602/neurorx.2.1.86</pub-id><pub-id pub-id-type="pmcid">PMC539326</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><name name-style="western"><surname>Girardin</surname><given-names>F</given-names></name><article-title>Membrane transporter proteins: a challenge for CNS drug development</article-title><source>Dialogues Clin Neurosci</source><year>2006</year><volume>8</volume><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">17117613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31887/DCNS.2006.8.3/fgirardin</pub-id><pub-id pub-id-type="pmcid">PMC3181821</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><name name-style="western"><surname>Schinkel</surname><given-names>AH</given-names></name><name name-style="western"><surname>Smit</surname><given-names>JJM</given-names></name><name name-style="western"><surname>van Tellingen</surname><given-names>O</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Wagenaar</surname><given-names>E</given-names></name><name name-style="western"><surname>van Deemter</surname><given-names>L</given-names></name><name name-style="western"><surname>Mol</surname><given-names>CAAM</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>MA</given-names></name><name name-style="western"><surname>Robanus-Maandag</surname><given-names>EC</given-names></name><name name-style="western"><surname>te Riele</surname><given-names>HPJ</given-names></name><name name-style="western"><surname>Berns</surname><given-names>AJM</given-names></name><name name-style="western"><surname>Borst</surname><given-names>P</given-names></name><article-title>Disruption of the Mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood&#8211;brain barrier and to increased sensitivity to drugs</article-title><source>Cell</source><year>1994</year><volume>77</volume><fpage>491</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90212-7</pub-id><pub-id pub-id-type="pmid">7910522</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><name name-style="western"><surname>Uchida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohtsuki</surname><given-names>S</given-names></name><name name-style="western"><surname>Kamiie</surname><given-names>J</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>T</given-names></name><article-title>Blood&#8211;brain barrier [BBB] pharmacoproteomics [PPx]: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice</article-title><source>J Pharmacol Exp Ther</source><year>2012</year><volume>339</volume><fpage>579</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">21828264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.111.184200</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><name name-style="western"><surname>Borst</surname><given-names>P</given-names></name><name name-style="western"><surname>Evers</surname><given-names>R</given-names></name><name name-style="western"><surname>Kool</surname><given-names>M</given-names></name><name name-style="western"><surname>Wijnholds</surname><given-names>J</given-names></name><article-title>A family of drug transporters: the multidrug resistance-associated proteins</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>1295</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1093/jnci/92.16.1295</pub-id><pub-id pub-id-type="pmid">10944550</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><name name-style="western"><surname>Enokizono</surname><given-names>J</given-names></name><name name-style="western"><surname>Kusuhara</surname><given-names>H</given-names></name><name name-style="western"><surname>Ose</surname><given-names>A</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>AH</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name><article-title>Quantitative investigation of the role of breast cancer resistance protein [bcrp/<italic toggle="yes">Abcg2</italic>] in limiting brain and testis penetration of xenobiotic compounds</article-title><source>Drug Metab. Disp</source><year>2008</year><volume>36</volume><fpage>995</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1124/dmd.107.019257</pub-id><pub-id pub-id-type="pmid">18322075</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><name name-style="western"><surname>Borst</surname><given-names>P</given-names></name><name name-style="western"><surname>Elferink</surname><given-names>RO</given-names></name><article-title>Mammalian ABC transporters in health and disease</article-title><source>Annu Rev Biochem</source><year>2002</year><volume>71</volume><fpage>537</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.71.102301.093055</pub-id><pub-id pub-id-type="pmid">12045106</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="book"><name name-style="western"><surname>Fenstermacher</surname><given-names>JD</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name><name name-style="western"><surname>Acuff</surname><given-names>V</given-names></name><name name-style="western"><surname>Lin</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bereczki</surname><given-names>D</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakata</surname><given-names>H</given-names></name><name name-style="western"><surname>Tajima</surname><given-names>A</given-names></name><name name-style="western"><surname>Hans</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Ghersi-Egea</surname><given-names>JF</given-names></name><name name-style="western"><surname>Finnegan</surname><given-names>W</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>G</given-names></name><name name-style="western"><surname>Haspel</surname><given-names>H</given-names></name><name name-style="western"><surname>Patlak</surname><given-names>C</given-names></name><person-group person-group-type="editor">Greenwood J, Begley DJ, Segal MB</person-group><article-title>The dependency of influx across the blood&#8211;brain barrier on blood flow and the apparent flow-independence of glucose influx during stress</article-title><source>New Concepts of a Blood&#8211;Brain Barrier</source><year>1995</year><publisher-name>New York, London: Plenum Press</publisher-name><fpage>89</fpage><lpage>101</lpage></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><name name-style="western"><surname>Faraci</surname><given-names>FM</given-names></name><article-title>Endothelium-derived vasoactive factors and regulation of the cerebral circulation</article-title><source>Neurosurg</source><year>1993</year><volume>33</volume><fpage>648</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1227/00006123-199310000-00014</pub-id><pub-id pub-id-type="pmid">8232805</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><name name-style="western"><surname>Brown</surname><given-names>PD</given-names></name><name name-style="western"><surname>Davies</surname><given-names>SL</given-names></name><name name-style="western"><surname>Speake</surname><given-names>T</given-names></name><name name-style="western"><surname>Millar</surname><given-names>ID</given-names></name><article-title>Molecular mechanisms of cerebrospinal fluid production</article-title><source>Neurosci</source><year>2004</year><volume>129</volume><fpage>957</fpage><lpage>970</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2004.07.003</pub-id><pub-id pub-id-type="pmcid">PMC1890044</pub-id><pub-id pub-id-type="pmid">15561411</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><name name-style="western"><surname>Davson</surname><given-names>H</given-names></name><name name-style="western"><surname>Segal</surname><given-names>MB</given-names></name><article-title>The effects of some inhibitors and accelerators of sodium transport on the turnover of <sup>22</sup>Na in the cerebrospinal fluid and the brain</article-title><source>J Physiol</source><year>1970</year><volume>209</volume><fpage>139</fpage><lpage>153</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/jphysiol.1970.sp009159</pub-id><pub-id pub-id-type="pmcid">PMC1396036</pub-id><pub-id pub-id-type="pmid">5499038</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><name name-style="western"><surname>Proescholdt</surname><given-names>MG</given-names></name><name name-style="western"><surname>Hutto</surname><given-names>B</given-names></name><name name-style="western"><surname>Brady</surname><given-names>LS</given-names></name><name name-style="western"><surname>Herkenham</surname><given-names>M</given-names></name><article-title>Studies of cerebrospinal fluid flow and penetration into brain following lateral ventricle and cisterna magna injections of the tracer [<sup>14</sup>C]inulin in rat</article-title><source>Neurosci</source><year>2000</year><volume>95</volume><fpage>577</fpage><lpage>592</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0306-4522(99)00417-0</pub-id><pub-id pub-id-type="pmid">10658638</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><name name-style="western"><surname>Abbott</surname><given-names>NJ</given-names></name><article-title>Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology</article-title><source>Neurochem Int</source><year>2004</year><volume>45</volume><fpage>545</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2003.11.006</pub-id><pub-id pub-id-type="pmid">15186921</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><name name-style="western"><surname>Del Bigio</surname><given-names>MR</given-names></name><article-title>The ependyma: a protective barrier between brain and cerebrospinal fluid</article-title><source>Glia</source><year>1995</year><volume>14</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/glia.440140102</pub-id><pub-id pub-id-type="pmid">7615341</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kalvass</surname><given-names>JC</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>TS</given-names></name><article-title>Influence of nonspecific brain and plasma binding of CNS exposure: implications for rational drug discovery</article-title><source>Biopharm Drug Dispos</source><year>2002</year><volume>23</volume><fpage>327</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1002/bdd.325</pub-id><pub-id pub-id-type="pmid">12415573</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><name name-style="western"><surname>Marroni</surname><given-names>M</given-names></name><name name-style="western"><surname>Marchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Cucullo</surname><given-names>L</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Signorelli</surname><given-names>K</given-names></name><name name-style="western"><surname>Janigro</surname><given-names>D</given-names></name><article-title>Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy</article-title><source>Curr Drug Targets</source><year>2003</year><volume>4</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.2174/1389450033491109</pub-id><pub-id pub-id-type="pmid">12699350</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><article-title>Active-site concentrations of chemicals &#8211; are they a better predictor of effect than plasma/organ/tissue concentrations?</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2009</year><volume>106</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">20050843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-7843.2009.00517.x</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><name name-style="western"><surname>Minn</surname><given-names>A</given-names></name><name name-style="western"><surname>Ghersi-Egea</surname><given-names>JF</given-names></name><name name-style="western"><surname>Perrin</surname><given-names>R</given-names></name><name name-style="western"><surname>Leininger</surname><given-names>B</given-names></name><name name-style="western"><surname>Siest</surname><given-names>G</given-names></name><article-title>Drug metabolizing enzymes in the brain and cerebral microvessels</article-title><source>Brain Res</source><year>1991</year><volume>16</volume><fpage>65</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/0165-0173(91)90020-9</pub-id><pub-id pub-id-type="pmid">1907518</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ghersi-Egea</surname><given-names>J-F</given-names></name><name name-style="western"><surname>Perrin</surname><given-names>R</given-names></name><name name-style="western"><surname>Leininger-Muller</surname><given-names>B</given-names></name><name name-style="western"><surname>Grassiot</surname><given-names>M-C</given-names></name><name name-style="western"><surname>Jeandel</surname><given-names>C</given-names></name><name name-style="western"><surname>Floquet</surname><given-names>J</given-names></name><name name-style="western"><surname>Cuny</surname><given-names>G</given-names></name><name name-style="western"><surname>Siest</surname><given-names>G</given-names></name><name name-style="western"><surname>Minn</surname><given-names>A</given-names></name><article-title>Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain</article-title><source>Biochem Pharmacol</source><year>1993</year><volume>45</volume><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">8442765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(93)90139-n</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ghersi-Egea</surname><given-names>JF</given-names></name><name name-style="western"><surname>Leininger-Muller</surname><given-names>B</given-names></name><name name-style="western"><surname>Suleman</surname><given-names>G</given-names></name><name name-style="western"><surname>Siest</surname><given-names>G</given-names></name><name name-style="western"><surname>Minn</surname><given-names>A</given-names></name><article-title>Localization of drug-metabolizing enzyme activities to blood&#8211;brain interfaces and circumventricular organs</article-title><source>J Neurochem</source><year>1994</year><volume>62</volume><fpage>1089</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">8113796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1471-4159.1994.62031089.x</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><name name-style="western"><surname>Shawahna</surname><given-names>R</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Decl&#232;ves</surname><given-names>X</given-names></name><name name-style="western"><surname>Ohtsuki</surname><given-names>S</given-names></name><name name-style="western"><surname>Yousif</surname><given-names>S</given-names></name><name name-style="western"><surname>Dauchy</surname><given-names>S</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>A</given-names></name><name name-style="western"><surname>Chassoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Daumas-Duport</surname><given-names>C</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>PO</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Scherrmann</surname><given-names>JM</given-names></name><article-title>Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels</article-title><source>Mol Pharm</source><year>2011</year><volume>8</volume><fpage>1332</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1021/mp200129p</pub-id><pub-id pub-id-type="pmid">21707071</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><name name-style="western"><surname>Yassen</surname><given-names>A</given-names></name><name name-style="western"><surname>Olofsen</surname><given-names>E</given-names></name><name name-style="western"><surname>van Dorp</surname><given-names>E</given-names></name><name name-style="western"><surname>Sarton</surname><given-names>E</given-names></name><name name-style="western"><surname>Teppema</surname><given-names>L</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>Dahan</surname><given-names>A</given-names></name><article-title>Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers</article-title><source>Clin Pharmacokinet</source><year>2007</year><volume>46</volume><fpage>965</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.2165/00003088-200746110-00004</pub-id><pub-id pub-id-type="pmid">17922561</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><name name-style="western"><surname>Casta&#241;eda-Hern&#225;ndez</surname><given-names>G</given-names></name><name name-style="western"><surname>Granados-Soto</surname><given-names>V</given-names></name><article-title>Considerations on pharmacodynamics and pharmacokinetics: can everything be explained by the extent of drug binding to its receptor?</article-title><source>Can J Physiol Pharmacol</source><year>2000</year><volume>78</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1139/y99-134</pub-id><pub-id pub-id-type="pmid">10721811</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><name name-style="western"><surname>Karssen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>OC</given-names></name><name name-style="western"><surname>van der Sandt</surname><given-names>IC</given-names></name><name name-style="western"><surname>Lucassen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>EC</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>AG</given-names></name><name name-style="western"><surname>de Kloet</surname><given-names>ER</given-names></name><article-title>Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain</article-title><source>Endocrinol</source><year>2001</year><volume>142</volume><fpage>2686</fpage><lpage>2694</lpage><pub-id pub-id-type="doi">10.1210/en.142.6.2686</pub-id><pub-id pub-id-type="pmid">11356720</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><name name-style="western"><surname>Marzolini</surname><given-names>C</given-names></name><name name-style="western"><surname>Paus</surname><given-names>E</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>RB</given-names></name><article-title>Polymorphisms in human <italic toggle="yes">MDR1</italic> [P-glycoprotein]: recent advances and clinical relevance</article-title><source>Clin Pharmacol Ther</source><year>2004</year><volume>75</volume><fpage>13</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2003.09.012</pub-id><pub-id pub-id-type="pmid">14749689</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>MS</given-names></name><article-title>Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants</article-title><source>Drugs Today (Barc)</source><year>2007</year><volume>43</volume><fpage>569</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1358/dot.2007.43.8.1130447</pub-id><pub-id pub-id-type="pmid">17925888</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><name name-style="western"><surname>Swan</surname><given-names>GE</given-names></name><name name-style="western"><surname>Lessov-Schlaggar</surname><given-names>CN</given-names></name><name name-style="western"><surname>Krasnow</surname><given-names>RE</given-names></name><name name-style="western"><surname>Wilhelmsen</surname><given-names>KC</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>P</given-names></name><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><article-title>Genetic and environmental sources of variation in heart rate response to infused nicotine in twins</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2007</year><volume>16</volume><fpage>1057</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-1093</pub-id><pub-id pub-id-type="pmid">17548663</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><name name-style="western"><surname>Xia</surname><given-names>CQ</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><name name-style="western"><surname>Pimprale</surname><given-names>S</given-names></name><name name-style="western"><surname>Fox</surname><given-names>L</given-names></name><name name-style="western"><surname>Patten</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Crespi</surname><given-names>CL</given-names></name><name name-style="western"><surname>Miwa</surname><given-names>G</given-names></name><name name-style="western"><surname>Gan</surname><given-names>LS</given-names></name><article-title>Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays</article-title><source>Mol Pharm</source><year>2006</year><volume>3</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1021/mp050034j</pub-id><pub-id pub-id-type="pmid">16686372</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><name name-style="western"><surname>Suzuyama</surname><given-names>N</given-names></name><name name-style="western"><surname>Katoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshitomi</surname><given-names>S</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Asashi</surname><given-names>S</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>T</given-names></name><article-title>Species differences of inhibitory effects on P-glycoprotein-mediated drug transport</article-title><source>J Pharm Sci</source><year>2007</year><volume>96</volume><fpage>1609</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1002/jps.20787</pub-id><pub-id pub-id-type="pmid">17094122</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><name name-style="western"><surname>Krause</surname><given-names>DN</given-names></name><name name-style="western"><surname>Duckles</surname><given-names>SP</given-names></name><name name-style="western"><surname>Pelligrino</surname><given-names>DA</given-names></name><article-title>Influence of sex steroid hormones on cerebrovascular function</article-title><source>J Appl Physiol</source><year>2006</year><volume>101</volume><fpage>1252</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.01095.2005</pub-id><pub-id pub-id-type="pmid">16794020</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><name name-style="western"><surname>Shulman</surname><given-names>LM</given-names></name><article-title>Gender differences in Parkinson&#8217;s disease</article-title><source>Gend Med</source><year>2007</year><volume>4</volume><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/S1550-8579(07)80003-9</pub-id><pub-id pub-id-type="pmid">17584622</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><name name-style="western"><surname>Gr&#252;nder</surname><given-names>G</given-names></name><name name-style="western"><surname>Wetzel</surname><given-names>H</given-names></name><name name-style="western"><surname>Schl&#246;sser</surname><given-names>R</given-names></name><name name-style="western"><surname>Anghelescu</surname><given-names>I</given-names></name><name name-style="western"><surname>Hillert</surname><given-names>A</given-names></name><name name-style="western"><surname>Lange</surname><given-names>K</given-names></name><name name-style="western"><surname>Hiemke</surname><given-names>C</given-names></name><name name-style="western"><surname>Benkert</surname><given-names>O</given-names></name><article-title>Neuroendocrine response to antipsychotics: effects of drug type and gender</article-title><source>Biol Psychiat</source><year>1999</year><volume>45</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(98)00125-5</pub-id><pub-id pub-id-type="pmid">9894580</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><name name-style="western"><surname>Pleym</surname><given-names>H</given-names></name><name name-style="western"><surname>Spigset</surname><given-names>O</given-names></name><name name-style="western"><surname>Kharasch</surname><given-names>ED</given-names></name><name name-style="western"><surname>Dale</surname><given-names>O</given-names></name><article-title>Gender differences in drug effects: implications for anesthesiologists</article-title><source>Acta Anaesthesiol Scand</source><year>2003</year><volume>47</volume><fpage>241</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1034/j.1399-6576.2003.00036.x</pub-id><pub-id pub-id-type="pmid">12648189</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bauer</surname><given-names>M</given-names></name><name name-style="western"><surname>Karch</surname><given-names>R</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>F</given-names></name><name name-style="western"><surname>Abrahim</surname><given-names>A</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>CC</given-names></name><name name-style="western"><surname>Kletter</surname><given-names>K</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeitlinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Langer</surname><given-names>O</given-names></name><article-title>Age dependency of cerebral P-gp function measured with [R]-[<sup>11</sup>C]verapamil and PET</article-title><source>Eur J Clin Pharmacol</source><year>2009</year><volume>65</volume><fpage>941</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1007/s00228-009-0709-5</pub-id><pub-id pub-id-type="pmid">19655132</pub-id><pub-id pub-id-type="pmcid">PMC3689922</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name><name name-style="western"><surname>Timiras</surname><given-names>PS</given-names></name><article-title>Age-dependent activation of glucocorticoid receptors in the cerebral hemispheres of male rats</article-title><source>Brain Res</source><year>1987</year><volume>433</volume><fpage>285</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">3690338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-3806(87)90033-2</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><name name-style="western"><surname>Magnusson</surname><given-names>KR</given-names></name><name name-style="western"><surname>Brim</surname><given-names>BL</given-names></name><name name-style="western"><surname>Das</surname><given-names>SR</given-names></name><article-title>Selective vulnerabilities of N-methyl-D-aspartate (NMDA) receptors during brain aging</article-title><source>Front Aging Neurosci</source><year>2010</year><volume>19</volume><issue>2</issue><fpage>11</fpage><pub-id pub-id-type="pmid">20552049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2010.00011</pub-id><pub-id pub-id-type="pmcid">PMC2874396</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><name name-style="western"><surname>Gagliese</surname><given-names>L</given-names></name><name name-style="western"><surname>Melzack</surname><given-names>R</given-names></name><article-title>Age differences in nociception and pain behaviours in the rat</article-title><source>Neurosci Biobehav Rev</source><year>2000</year><volume>24</volume><fpage>843</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1016/S0149-7634(00)00041-5</pub-id><pub-id pub-id-type="pmid">11118609</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><name name-style="western"><surname>Strong</surname><given-names>R</given-names></name><article-title>Neurochemical changes in the aging human brain: implications for behavioral impairment and neurodegenerative disease</article-title><source>Geriatrics</source><year>1998</year><volume>53</volume><issue>Suppl 1</issue><fpage>S9</fpage><lpage>S12</lpage><pub-id pub-id-type="pmid">9745628</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mulder</surname><given-names>M</given-names></name><name name-style="western"><surname>Blokland</surname><given-names>A</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Schulten</surname><given-names>H</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>AH</given-names></name><name name-style="western"><surname>Terwel</surname><given-names>D</given-names></name><name name-style="western"><surname>Honig</surname><given-names>W</given-names></name><name name-style="western"><surname>de Kloet</surname><given-names>ER</given-names></name><name name-style="western"><surname>Havekes</surname><given-names>LM</given-names></name><name name-style="western"><surname>Steinbusch</surname><given-names>HW</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>EC</given-names></name><article-title>Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood&#8211;brain barrier during aging</article-title><source>Lab Invest</source><year>2001</year><volume>81</volume><fpage>953</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3780307</pub-id><pub-id pub-id-type="pmid">11454984</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ho</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Talcott</surname><given-names>ST</given-names></name><name name-style="western"><surname>Ono</surname><given-names>K</given-names></name><name name-style="western"><surname>Teplow</surname><given-names>D</given-names></name><name name-style="western"><surname>Humala</surname><given-names>N</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A</given-names></name><name name-style="western"><surname>Percival</surname><given-names>SS</given-names></name><name name-style="western"><surname>Ferruzzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Janle</surname><given-names>E</given-names></name><name name-style="western"><surname>Dickstein</surname><given-names>DL</given-names></name><name name-style="western"><surname>Pasinetti</surname><given-names>GM</given-names></name><article-title>Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer&#8217;s disease-type neuropathology and cognitive deterioration</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>16</volume><fpage>59</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">19158422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2009-0916</pub-id><pub-id pub-id-type="pmcid">PMC2857553</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><name name-style="western"><surname>Clinckers</surname><given-names>R</given-names></name><name name-style="western"><surname>Smolders</surname><given-names>I</given-names></name><name name-style="western"><surname>Michotte</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ebinger</surname><given-names>G</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>Voskuyl</surname><given-names>RA</given-names></name><name name-style="western"><surname>Della Pasqua</surname><given-names>O</given-names></name><article-title>Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain</article-title><source>Br J Pharmacol</source><year>2008</year><volume>155</volume><fpage>1127</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">18836479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjp.2008.366</pub-id><pub-id pub-id-type="pmcid">PMC2597256</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bolwig</surname><given-names>TG</given-names></name><name name-style="western"><surname>Hertz</surname><given-names>MM</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>OB</given-names></name><name name-style="western"><surname>Spotoft</surname><given-names>H</given-names></name><name name-style="western"><surname>Rafaelsen</surname><given-names>OJ</given-names></name><article-title>The permeability of the blood&#8211;brain barrier during electrically induced seizures in man</article-title><source>Eur J Clin Invest</source><year>1977</year><volume>7</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.1977.tb01578.x</pub-id><pub-id pub-id-type="pmid">404164</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><name name-style="western"><surname>Langford</surname><given-names>D</given-names></name><name name-style="western"><surname>Grigorian</surname><given-names>A</given-names></name><name name-style="western"><surname>Hurford</surname><given-names>R</given-names></name><name name-style="western"><surname>Adame</surname><given-names>A</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>L</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E</given-names></name><article-title>Altered P-gp expression in AIDS patients with HIV encephalitis</article-title><source>J Neuropathol Exp Neurol</source><year>2004</year><volume>63</volume><fpage>1038</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">15535131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/63.10.1038</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><name name-style="western"><surname>Tunblad</surname><given-names>K</given-names></name><name name-style="western"><surname>Ederoth</surname><given-names>P</given-names></name><name name-style="western"><surname>Gardenfors</surname><given-names>A</given-names></name><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><name name-style="western"><surname>Nordstrom</surname><given-names>CH</given-names></name><article-title>Altered brain exposure of morphine in experimental meningitis studied with microdialysis</article-title><source>Acta Anaesthesiol Scand</source><year>2004</year><volume>48</volume><fpage>294</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1111/j.0001-5172.2003.0311.x</pub-id><pub-id pub-id-type="pmid">14982561</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ravenstijn</surname><given-names>PG</given-names></name><name name-style="western"><surname>Merlini</surname><given-names>M</given-names></name><name name-style="western"><surname>Hameetman</surname><given-names>M</given-names></name><name name-style="western"><surname>Murray</surname><given-names>TK</given-names></name><name name-style="western"><surname>Ward</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>H</given-names></name><name name-style="western"><surname>Ball</surname><given-names>G</given-names></name><name name-style="western"><surname>Mottart</surname><given-names>C</given-names></name><name name-style="western"><surname>de Ville de Goyet</surname><given-names>C</given-names></name><name name-style="western"><surname>Lemarchand</surname><given-names>T</given-names></name><name name-style="western"><surname>van Belle</surname><given-names>K</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>De Lange</surname><given-names>EC</given-names></name><article-title>The exploration of rotenone as a toxin for inducing Parkinson&#8217;s disease in rats, for application in BBB transport and PK-PD experiments</article-title><source>J Pharmacol Toxicol Meth</source><year>2007</year><volume>57</volume><fpage>114</fpage><lpage>130</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vascn.2007.10.003</pub-id><pub-id pub-id-type="pmid">18155613</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ravenstijn</surname><given-names>PGM</given-names></name><name name-style="western"><surname>Drenth</surname><given-names>H</given-names></name><name name-style="western"><surname>Baatje</surname><given-names>MS</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><article-title>Evaluation of BBB transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson&#8217;s disease</article-title><source>Fluids Barriers CNS</source><year>2012</year><volume>9</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/2045-8118-9-4</pub-id><pub-id pub-id-type="pmid">22316420</pub-id><pub-id pub-id-type="pmcid">PMC3298802</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><name name-style="western"><surname>Cleton</surname><given-names>A</given-names></name><name name-style="western"><surname>Odman</surname><given-names>J</given-names></name><name name-style="western"><surname>Van der Graaf</surname><given-names>PH</given-names></name><name name-style="western"><surname>Ghijsen</surname><given-names>W</given-names></name><name name-style="western"><surname>Voskuyl</surname><given-names>R</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><article-title>Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam</article-title><source>Pharm Res</source><year>2000</year><volume>17</volume><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1023/A:1007505223519</pub-id><pub-id pub-id-type="pmid">10801221</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><name name-style="western"><surname>Tel</surname><given-names>BC</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>BY</given-names></name><name name-style="western"><surname>Cannizzaro</surname><given-names>C</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>RK</given-names></name><name name-style="western"><surname>Rose</surname><given-names>S</given-names></name><name name-style="western"><surname>Jenner</surname><given-names>P</given-names></name><article-title>Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets</article-title><source>Neurosci</source><year>2002</year><volume>115</volume><fpage>1047</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(02)00535-3</pub-id><pub-id pub-id-type="pmid">12453478</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><name name-style="western"><surname>Vinkers</surname><given-names>CH</given-names></name><name name-style="western"><surname>van Oorschot</surname><given-names>R</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>E&#216;</given-names></name><name name-style="western"><surname>Cook</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>HH</given-names></name><name name-style="western"><surname>Groenink</surname><given-names>L</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>B</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>NR</given-names></name><article-title>GABA(A) receptor &#945; subunits differentially contribute to diazepam tolerance after chronic treatment</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e43054</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0043054</pub-id><pub-id pub-id-type="pmid">22912786</pub-id><pub-id pub-id-type="pmcid">PMC3418228</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>M</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>H</given-names></name><name name-style="western"><surname>Patel</surname><given-names>VB</given-names></name><name name-style="western"><surname>Manchikanti</surname><given-names>L</given-names></name><article-title>A comprehensive review of opioid-induced hyperalgesia</article-title><source>Pain Physician</source><year>2011</year><volume>14</volume><fpage>145</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">21412369</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><name name-style="western"><surname>Boxenbaum</surname><given-names>H</given-names></name><article-title>Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics</article-title><source>J Pharmacokin Biopharm</source><year>1982</year><volume>10</volume><fpage>201</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1007/BF01062336</pub-id><pub-id pub-id-type="pmid">7120049</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ings</surname><given-names>RMJ</given-names></name><article-title>Interspecies scaling and comparisons in drug development and toxicogenetics</article-title><source>Xenobiotica</source><year>1990</year><volume>20</volume><fpage>1201</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.3109/00498259009046839</pub-id><pub-id pub-id-type="pmid">2275215</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mahmood</surname><given-names>I</given-names></name><name name-style="western"><surname>Balian</surname><given-names>JD</given-names></name><article-title>The pharmacokinetic principles behind scaling from preclinical results to phase I protocols</article-title><source>Clin Pharmacokin</source><year>1999</year><volume>36</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199936010-00001</pub-id><pub-id pub-id-type="pmid">9989339</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bonati</surname><given-names>M</given-names></name><name name-style="western"><surname>Latini</surname><given-names>R</given-names></name><name name-style="western"><surname>Tognini</surname><given-names>G</given-names></name><name name-style="western"><surname>Young</surname><given-names>JF</given-names></name><name name-style="western"><surname>Garattini</surname><given-names>S</given-names></name><article-title>Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse</article-title><source>Drug Metab Rev</source><year>1984</year><volume>15</volume><fpage>1355</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.3109/03602538409029964</pub-id><pub-id pub-id-type="pmid">6543526</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><name name-style="western"><surname>Van Steeg</surname><given-names>T</given-names></name><name name-style="western"><surname>Krekels</surname><given-names>EHJ</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><article-title>Experimental alteration of serum AGP and albumin concentrations in the Rat, an approach to assess the impact of changes in serum protein binding on pharmacodynamics</article-title><source>J Pharmacol Toxicol Meth</source><year>2007</year><volume>56</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.vascn.2007.02.002</pub-id><pub-id pub-id-type="pmid">17376707</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><name name-style="western"><surname>Van Steeg</surname><given-names>T</given-names></name><name name-style="western"><surname>Krekels</surname><given-names>EHJ</given-names></name><name name-style="western"><surname>Freijer</surname><given-names>J</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><article-title>Effect of altered AGP plasma binding on heart rate changes by S[&#8722;]-propranolol in rats using mechanism-based estimations of in vivo receptor affinity [KB, vivo]</article-title><source>J Pharm Sci</source><year>2010</year><volume>99</volume><fpage>2511</fpage><lpage>2520</lpage><pub-id pub-id-type="pmid">20020526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.22014</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><name name-style="western"><surname>Fox</surname><given-names>E</given-names></name><name name-style="western"><surname>Bates</surname><given-names>SE</given-names></name><article-title>Tariquidar [XR9576]: a P-glycoprotein drug efflux pump inhibitor</article-title><source>Expert Rev Anticancer Ther</source><year>2007</year><volume>7</volume><fpage>447</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1586/14737140.7.4.447</pub-id><pub-id pub-id-type="pmid">17428165</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><name name-style="western"><surname>Furchgott</surname><given-names>RF</given-names></name><article-title>The use of &#946;-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes</article-title><source>Adv Drug Res</source><year>1966</year><volume>3</volume><fpage>21</fpage><lpage>55</lpage></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><name name-style="western"><surname>Garrido</surname><given-names>M</given-names></name><name name-style="western"><surname>Gubbens-Stibbe</surname><given-names>J</given-names></name><name name-style="western"><surname>Tukker</surname><given-names>E</given-names></name><name name-style="western"><surname>Cox</surname><given-names>E</given-names></name><name name-style="western"><surname>von Frijtag</surname><given-names>J</given-names></name><name name-style="western"><surname>K&#252;nzel</surname><given-names>D</given-names></name><name name-style="western"><surname>IJzerman</surname><given-names>A</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>PH</given-names></name><article-title>Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor &#8220;knockdown&#8221; in vivo</article-title><source>Pharm Res</source><year>2000</year><volume>17</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1023/A:1007513812018</pub-id><pub-id pub-id-type="pmid">10955836</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><name name-style="western"><surname>Syv&#228;nen</surname><given-names>S</given-names></name><name name-style="western"><surname>Schenke</surname><given-names>M</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>D-J</given-names></name><name name-style="western"><surname>Voskuyl</surname><given-names>RA</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><article-title>Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry &#8211; a study in rats subjected to status epilepticus by kainate</article-title><source>AAPS J</source><year>2012</year><volume>14</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1208/s12248-011-9318-1</pub-id><pub-id pub-id-type="pmid">22215264</pub-id><pub-id pub-id-type="pmcid">PMC3281999</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><name name-style="western"><surname>Gabrielsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Green</surname><given-names>AR</given-names></name><article-title>Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should Be a vital component in integrative pharmacology</article-title><source>J Pharmacol Exp Ther</source><year>2009</year><volume>331</volume><fpage>767</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1124/jpet.109.157172</pub-id><pub-id pub-id-type="pmid">19779129</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><name name-style="western"><surname>Breimer</surname><given-names>DD</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><article-title>Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The &#8216;wooden shoe&#8217; paradigm</article-title><source>Clin Pharmacokin</source><year>1997</year><volume>32</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.2165/00003088-199732040-00001</pub-id><pub-id pub-id-type="pmid">9113436</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>EC</given-names></name><name name-style="western"><surname>Della Pasqua</surname><given-names>OE</given-names></name><name name-style="western"><surname>Ploeger</surname><given-names>BA</given-names></name><name name-style="western"><surname>Voskuyl</surname><given-names>RA</given-names></name><article-title>Mechanism-based pharmacokinetic-pharmacodynamic (PKPD) modeling in translational drug research</article-title><source>Trends Pharmacol Sci</source><year>2008</year><volume>29</volume><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2008.01.007</pub-id><pub-id pub-id-type="pmid">18353445</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ploeger</surname><given-names>BA</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>PH</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><article-title>Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic [PK-PD] modeling</article-title><source>Drug Metab Pharmacokinet</source><year>2009</year><volume>24</volume><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.2133/dmpk.24.3</pub-id><pub-id pub-id-type="pmid">19252332</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><name name-style="western"><surname>Rowland</surname><given-names>M</given-names></name><name name-style="western"><surname>Peck</surname><given-names>C</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>G</given-names></name><article-title>Physiologically-based pharmacokinetics in drug development and regulatory science</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2011</year><volume>51</volume><fpage>45</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010510-100540</pub-id><pub-id pub-id-type="pmid">20854171</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><name name-style="western"><surname>Shen</surname><given-names>DD</given-names></name><name name-style="western"><surname>Artru</surname><given-names>AA</given-names></name><name name-style="western"><surname>Adkison</surname><given-names>KK</given-names></name><article-title>Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics</article-title><source>Adv Drug Del Rev</source><year>2004</year><volume>56</volume><fpage>1825</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2004.07.011</pub-id><pub-id pub-id-type="pmid">15381336</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><name name-style="western"><surname>Westerhout</surname><given-names>J</given-names></name><name name-style="western"><surname>Ploeger</surname><given-names>B</given-names></name><name name-style="western"><surname>Smeets</surname><given-names>J</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><article-title>Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats</article-title><source>AAPS J</source><year>2012</year><volume>14</volume><fpage>543</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1208/s12248-012-9366-1</pub-id><pub-id pub-id-type="pmid">22588644</pub-id><pub-id pub-id-type="pmcid">PMC3385827</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="book"><name name-style="western"><surname>Paxinos</surname><given-names>G</given-names></name><name name-style="western"><surname>Watson</surname><given-names>C</given-names></name><source>The Rat Brain in Stereotaxic Coordinate</source><year>1998</year><edition>Fourth</edition><publisher-name>New York: Academic Press, Spiral Bound</publisher-name></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bannwarth</surname><given-names>B</given-names></name><name name-style="western"><surname>Netter</surname><given-names>P</given-names></name><name name-style="western"><surname>Lapicque</surname><given-names>F</given-names></name><name name-style="western"><surname>Gillet</surname><given-names>P</given-names></name><name name-style="western"><surname>P&#233;r&#233;</surname><given-names>P</given-names></name><name name-style="western"><surname>Boccard</surname><given-names>E</given-names></name><name name-style="western"><surname>Royer</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Gaucher</surname><given-names>A</given-names></name><article-title>Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol</article-title><source>Br J Clin Pharmacol</source><year>1992</year><volume>34</volume><fpage>79</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1992.tb04112.x</pub-id><pub-id pub-id-type="pmid">1633071</pub-id><pub-id pub-id-type="pmcid">PMC1381380</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><name name-style="western"><surname>Dhuria</surname><given-names>SV</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>LR</given-names></name><name name-style="western"><surname>Frey</surname><given-names>WH</given-names></name><article-title>Intranasal delivery to the central nervous system: Mechanisms and experimental considerations</article-title><source>J Pharm Sci</source><year>2009</year><volume>99</volume><fpage>1654</fpage><lpage>1673</lpage><pub-id pub-id-type="pmid">19877171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.21924</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><name name-style="western"><surname>Frey</surname><given-names>WH</given-names></name><article-title>Intranasal delivery: bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord</article-title><source>Drug Deliv Technol</source><year>2002</year><volume>2</volume><fpage>46</fpage><lpage>49</lpage></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bagger</surname><given-names>M</given-names></name><name name-style="western"><surname>Bechgaard</surname><given-names>E</given-names></name><article-title>A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug</article-title><source>Int J Pharm</source><year>2004</year><volume>269</volume><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2003.09.017</pub-id><pub-id pub-id-type="pmid">14706243</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><name name-style="western"><surname>Illum</surname><given-names>L</given-names></name><article-title>Transport of drugs from the nasal cavity to the central nervous system</article-title><source>Eur J Pharm Sci</source><year>2000</year><volume>11</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/S0928-0987(00)00087-7</pub-id><pub-id pub-id-type="pmid">10913748</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><name name-style="western"><surname>Illum</surname><given-names>L</given-names></name><article-title>Is nose-to-brain transport of drugs in man a reality?</article-title><source>J Pharm Pharmacol</source><year>2004</year><volume>56</volume><fpage>3</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1211/0022357022539</pub-id><pub-id pub-id-type="pmid">14979996</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><name name-style="western"><surname>Stevens</surname><given-names>J</given-names></name><name name-style="western"><surname>Suidgeest</surname><given-names>E</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>PH</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><article-title>A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs</article-title><source>Pharm Res</source><year>2009</year><volume>26</volume><fpage>1911</fpage><lpage>1917</lpage><pub-id pub-id-type="doi">10.1007/s11095-009-9907-1</pub-id><pub-id pub-id-type="pmid">19452129</pub-id><pub-id pub-id-type="pmcid">PMC2705718</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><name name-style="western"><surname>Stevens</surname><given-names>J</given-names></name><name name-style="western"><surname>Ploeger</surname><given-names>B</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>PH</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name><article-title>Systemic- and direct nose-to-brain transport in the rat, a mechanistic pharmacokinetic model for remoxipride after intravenous and intranasal administration</article-title><source>Drug Metab Disp</source><year>2011</year><volume>39</volume><fpage>2275</fpage><lpage>2282</lpage><pub-id pub-id-type="doi">10.1124/dmd.111.040782</pub-id><pub-id pub-id-type="pmid">21903866</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><name name-style="western"><surname>Freeman</surname><given-names>ME</given-names></name><name name-style="western"><surname>Kanyicska</surname><given-names>B</given-names></name><name name-style="western"><surname>Lerant</surname><given-names>A</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>G</given-names></name><article-title>Prolactin: structure, function, and regulation of secretion</article-title><source>Physiol Rev</source><year>2000</year><volume>80</volume><fpage>1523</fpage><lpage>1631</lpage><pub-id pub-id-type="pmid">11015620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.2000.80.4.1523</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><name name-style="western"><surname>Fitzgerald</surname><given-names>P</given-names></name><name name-style="western"><surname>Dinan</surname><given-names>TG</given-names></name><article-title>Prolactin and dopamine: What is the connection? A Review Article</article-title><source>J Psychopharmacol</source><year>2008</year><volume>22</volume><issue>suppl</issue><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1177/0269216307087148</pub-id><pub-id pub-id-type="pmid">18477617</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><name name-style="western"><surname>Stevens</surname><given-names>J</given-names></name><name name-style="western"><surname>Ploeger</surname><given-names>BA</given-names></name><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><name name-style="western"><surname>Osswald</surname><given-names>G</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>PH</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>EC</given-names></name><article-title>Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2012</year><volume>39</volume><fpage>463</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1007/s10928-012-9262-4</pub-id><pub-id pub-id-type="pmid">22791078</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Petersson</surname><given-names>KJF</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><article-title>An Agonist-Antagonist Interaction Model for Prolactin Release Following Risperidone and Paliperidone Treatment</article-title><source>Clin Pharmacol Ther</source><year>2008</year><volume>85</volume><fpage>409</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">19109590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.234</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><name name-style="western"><surname>Movin-Osswald</surname><given-names>G</given-names></name><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><name name-style="western"><surname>Von Bahr</surname><given-names>C</given-names></name><name name-style="western"><surname>Eneroth</surname><given-names>P</given-names></name><name name-style="western"><surname>Walton-Bowen</surname><given-names>K</given-names></name><article-title>Influence of the dosing interval on prolactin release after remoxipride</article-title><source>Br J Clin Pharmacol</source><year>1995</year><volume>39</volume><fpage>503</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1995.tb04487.x</pub-id><pub-id pub-id-type="pmid">7669486</pub-id><pub-id pub-id-type="pmcid">PMC1365057</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><name name-style="western"><surname>Movin-Osswald</surname><given-names>G</given-names></name><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><article-title>Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects</article-title><source>J Pharmaco Exp Ther</source><year>1995</year><volume>274</volume><fpage>921</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">7636755</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lav&#233;</surname><given-names>T</given-names></name><name name-style="western"><surname>Portmann</surname><given-names>R</given-names></name><name name-style="western"><surname>Schenker</surname><given-names>G</given-names></name><name name-style="western"><surname>Gianni</surname><given-names>A</given-names></name><name name-style="western"><surname>Guenzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Girometta</surname><given-names>MA</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>M</given-names></name><article-title>Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor</article-title><source>J Pharm Pharmacol</source><year>1999</year><volume>49</volume><fpage>178</fpage><lpage>183</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1211/0022357991772006</pub-id><pub-id pub-id-type="pmid">10197423</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kielbasa</surname><given-names>W</given-names></name><name name-style="western"><surname>Kalvass</surname><given-names>JC</given-names></name><name name-style="western"><surname>Stratford</surname><given-names>RE</given-names><suffix>Jr</suffix></name><article-title>Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats</article-title><source>Drug Metab Dispos</source><year>2009</year><volume>37</volume><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.023119</pub-id><pub-id pub-id-type="pmid">18936112</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kielbasa</surname><given-names>W</given-names></name><name name-style="western"><surname>Stratford</surname><given-names>RE</given-names><suffix>Jr</suffix></name><article-title>Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses</article-title><source>Drug Metab Dispos</source><year>2012</year><volume>40</volume><fpage>877</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1124/dmd.111.043554</pub-id><pub-id pub-id-type="pmid">22287668</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><name name-style="western"><surname>Yassen</surname><given-names>A</given-names></name><name name-style="western"><surname>Olofsen</surname><given-names>E</given-names></name><name name-style="western"><surname>Kan</surname><given-names>J</given-names></name><name name-style="western"><surname>Dahan</surname><given-names>A</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><article-title>Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine</article-title><source>Clin Pharmacokin</source><year>2007</year><volume>46</volume><fpage>433</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.2165/00003088-200746050-00005</pub-id><pub-id pub-id-type="pmid">17465641</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><name name-style="western"><surname>Zuideveld</surname><given-names>KP</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>PH</given-names></name><name name-style="western"><surname>Peletier</surname><given-names>LA</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><article-title>Allometric scaling of pharmacodynamic response: application to 5-HT<sub>1A</sub> receptor mediated responses from rat to man</article-title><source>Pharm Res</source><year>2007</year><volume>24</volume><fpage>2031</fpage><lpage>2039</lpage><pub-id pub-id-type="doi">10.1007/s11095-007-9336-y</pub-id><pub-id pub-id-type="pmid">17541734</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mager</surname><given-names>DE</given-names></name><name name-style="western"><surname>Woo</surname><given-names>S</given-names></name><name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></name><article-title>Scaling pharmacodynamics from <italic toggle="yes">in vitro</italic> and preclinical animal studies to humans</article-title><source>Drug Metab Pharmacokin</source><year>2009</year><volume>24</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.2133/dmpk.24.16</pub-id><pub-id pub-id-type="pmcid">PMC3727168</pub-id><pub-id pub-id-type="pmid">19252333</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><name name-style="western"><surname>Obach</surname><given-names>RS</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>JG</given-names></name><name name-style="western"><surname>Liston</surname><given-names>TE</given-names></name><name name-style="western"><surname>Silber</surname><given-names>BM</given-names></name><name name-style="western"><surname>Jones</surname><given-names>BC</given-names></name><name name-style="western"><surname>MacIntyre</surname><given-names>F</given-names></name><name name-style="western"><surname>Rance</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Wastall</surname><given-names>P</given-names></name><article-title>The prediction of human pharmacokinetic parameters from preclinical and <italic toggle="yes">in vitro</italic> metabolism data</article-title><source>J Pharmacol Exp Ther</source><year>1997</year><volume>283</volume><fpage>46</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">9336307</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ito</surname><given-names>H</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>K</given-names></name><name name-style="western"><surname>Goto</surname><given-names>R</given-names></name><name name-style="western"><surname>Kinomura</surname><given-names>S</given-names></name><name name-style="western"><surname>Taki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okada</surname><given-names>K</given-names></name><name name-style="western"><surname>Sato</surname><given-names>K</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T</given-names></name><name name-style="western"><surname>Kanno</surname><given-names>I</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>H</given-names></name><article-title>Database of normal human cerebral blood flow measured by SPECT: I. Comparison between I-123-IMP, Tc-99m-HMPAO, and Tc-99m-ECD as referred with O-15 labeled water PET and voxel-based morphometry</article-title><source>Ann Nucl Med</source><year>2006</year><volume>20</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1007/BF02985625</pub-id><pub-id pub-id-type="pmid">16615422</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kvernmo</surname><given-names>T</given-names></name><name name-style="western"><surname>Hartter</surname><given-names>S</given-names></name><name name-style="western"><surname>Burger</surname><given-names>E</given-names></name><article-title>A review of the receptor-binding and pharmacokinetic properties of dopamine agonists</article-title><source>Clin Therapeutics</source><year>2006</year><volume>28</volume><fpage>1065</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2006.08.004</pub-id><pub-id pub-id-type="pmid">16982285</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kvernmo</surname><given-names>T</given-names></name><name name-style="western"><surname>Houben</surname><given-names>J</given-names></name><name name-style="western"><surname>Sylte</surname><given-names>I</given-names></name><article-title>Receptor-binding and pharmacokinetic properties of dopaminergic agonists</article-title><source>Curr Top Med Chem</source><year>2008</year><volume>8</volume><fpage>1049</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.2174/156802608785161457</pub-id><pub-id pub-id-type="pmid">18691132</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mamo</surname><given-names>D</given-names></name><name name-style="western"><surname>Kapur</surname><given-names>S</given-names></name><name name-style="western"><surname>Shammi</surname><given-names>CM</given-names></name><name name-style="western"><surname>Papatheodorou</surname><given-names>G</given-names></name><name name-style="western"><surname>Mann</surname><given-names>S</given-names></name><name name-style="western"><surname>Therrien</surname><given-names>F</given-names></name><name name-style="western"><surname>Remington</surname><given-names>G</given-names></name><article-title>A PET study of dopamine D<sub>2</sub> and serotonin 5-HT<sub>2</sub> receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone</article-title><source>Am J Psych</source><year>2004</year><volume>161</volume><fpage>818</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.161.5.818</pub-id><pub-id pub-id-type="pmid">15121646</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ben-Jonathan</surname><given-names>N</given-names></name><name name-style="western"><surname>LaPensee</surname><given-names>CR</given-names></name><name name-style="western"><surname>LaPensee</surname><given-names>EW</given-names></name><article-title>What can we learn from rodents about prolactin in humans?</article-title><source>Endocr Rev</source><year>2008</year><volume>29</volume><fpage>1</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">18057139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/er.2007-0017</pub-id><pub-id pub-id-type="pmcid">PMC2244934</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>